

## University of Arkansas, Fayetteville ScholarWorks@UARK

---

### Patents Granted

---

2-17-2015

# Vaccine vectors and methods of enhancing immune responses

Luc Berghman

Walter G. Bottje

*University of Arkansas, Fayetteville*

Billy M. Hargis

*University of Arkansas, Fayetteville*

Sherryl Layton

*University of Arkansas, Fayetteville*

Follow this and additional works at: <http://scholarworks.uark.edu/pat>

---

### Recommended Citation

Berghman, Luc; Bottje, Walter G.; Hargis, Billy M.; and Layton, Sherryl, "Vaccine vectors and methods of enhancing immune responses" (2015). *Patents Granted*. Paper 13.

<http://scholarworks.uark.edu/pat/13>

This Patent is brought to you for free and open access by ScholarWorks@UARK. It has been accepted for inclusion in Patents Granted by an authorized administrator of ScholarWorks@UARK. For more information, please contact [scholar@uark.edu](mailto:scholar@uark.edu).



US008956618B2

(12) **United States Patent**  
**Berghman et al.**

(10) **Patent No.:** **US 8,956,618 B2**  
(45) **Date of Patent:** **Feb. 17, 2015**

(54) **VACCINE VECTORS AND METHODS OF ENHANCING IMMUNE RESPONSES**  
(75) Inventors: **Luc Berghman**, College Station, TX (US); **Walter Bottje**, Fayetteville, AR (US); **Billy Hargis**, Fayetteville, AR (US); **Sherryll Layton**, Rogers, AR (US)

(73) Assignees: **The Texas A&M University System**, College Station, TX (US); **The Board of Trustees of the University of Arkansas**, Little Rock, AR (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/574,504**

(22) PCT Filed: **Jan. 21, 2011**

(86) PCT No.: **PCT/US2011/022062**  
§ 371 (c)(1),  
(2), (4) Date: **Jul. 20, 2012**

(87) PCT Pub. No.: **WO2011/091255**  
PCT Pub. Date: **Jul. 28, 2011**

(65) **Prior Publication Data**  
US 2012/0282291 A1 Nov. 8, 2012

**Related U.S. Application Data**  
(60) Provisional application No. 61/297,098, filed on Jan. 21, 2010.

(51) **Int. Cl.**  
**A61K 49/00** (2006.01)  
**A61K 39/00** (2006.01)  
**A61K 39/12** (2006.01)  
**A61K 39/385** (2006.01)  
**A61K 39/145** (2006.01)  
**A61K 39/02** (2006.01)  
**A61K 45/00** (2006.01)  
**C12Q 1/68** (2006.01)

(52) **U.S. Cl.**  
CPC ..... **A61K 39/12** (2013.01); **A61K 2039/523** (2013.01); **A61K 2039/542** (2013.01); **A61K 2039/543** (2013.01); **A61K 2039/6006** (2013.01); **C12N 2760/16034** (2013.01)  
USPC ..... **424/184.1**; 424/185.1; 424/186.1; 424/192.1; 424/197.11; 424/206.1; 424/234.1; 424/282.1; 424/9.2; 435/6.15

(58) **Field of Classification Search**  
None  
See application file for complete search history.

(56) **References Cited**  
U.S. PATENT DOCUMENTS

5,683,700 A 11/1997 Charles et al.  
5,747,309 A 5/1998 Allan et al.  
5,962,406 A 10/1999 Armitage et al.

5,981,724 A 11/1999 Armitage et al.  
6,087,329 A 7/2000 Armitage et al.  
6,190,669 B1 2/2001 Noriega et al.  
6,264,951 B1 7/2001 Armitage et al.  
6,290,972 B1 9/2001 Armitage et al.  
6,306,387 B1 10/2001 Galan  
6,410,711 B1 6/2002 Armitage et al.  
6,479,258 B1 11/2002 Short  
6,713,279 B1 3/2004 Short  
6,902,906 B1 6/2005 Chatfield  
6,923,957 B2 8/2005 Lowery et al.  
6,923,958 B2 8/2005 Xiang et al.  
6,936,425 B1 8/2005 Hensel et al.  
6,969,609 B1 11/2005 Schlom et al.  
7,087,573 B1 8/2006 Lazarus et al.  
7,332,298 B2 2/2008 Kornbluth  
7,371,392 B2 5/2008 Tripp et al.  
7,405,270 B2 7/2008 Armitage et al.  
7,495,090 B2 2/2009 Prussak et al.  
7,842,501 B2 11/2010 Cai et al.  
7,928,213 B2 4/2011 Prussak et al.  
2001/0021386 A1 9/2001 Nuijten et al.  
2003/0165538 A1 9/2003 Goldman et al.  
2004/0006006 A9 1/2004 Armitage et al.  
2004/0047873 A1 3/2004 Al-Samkhani et al.  
2004/0053841 A1 3/2004 Tracey et al.  
2004/0141948 A1 7/2004 O'Keefe  
2004/0156851 A1 8/2004 Newman  
2004/0203039 A1 10/2004 Hensel et al.  
2004/0242481 A1 12/2004 Bianchi

(Continued)

FOREIGN PATENT DOCUMENTS

WO WO 93/08207 4/1993  
WO WO 95/14487 6/1995

(Continued)

OTHER PUBLICATIONS

GenBank AF178849, high mobility group protein HMGI [Gallus gallus], Sep. 27, 2000.\*  
GenBank ABW06338, matrix protein 2, partial [Influenza A virus (A/Indonesia/195H/2005(H5N1))], May 1, 2008.\*  
Harris et al., Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator, 2004, European Journal of Immunology, vol. 34, pp. 1503-1512.\*  
Liu, W. et al., "Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design," Microbes and Infection (2005) 7:171-177.

(Continued)

*Primary Examiner* — Benjamin P Blumel  
(74) *Attorney, Agent, or Firm* — Andrus Intellectual Property Law, LLP

(57) **ABSTRACT**

Provided herein are vaccine vectors including an antigenic polypeptide and an HMGB1 polypeptide present on the surface of the vaccine vector. Compositions comprising the vaccine vectors are also provided and include a pharmaceutically acceptable carrier, suitably a carrier for oral or nasal administration. Also provided are methods of enhancing immune responses, in particular antibody immune response and suitably an IgA response, by administering the vaccine vectors or compositions disclosed herein to a subject.

**24 Claims, 9 Drawing Sheets**

(56)

## References Cited

## U.S. PATENT DOCUMENTS

2005/0181994	A1	8/2005	Chamberlain et al.	
2005/0226888	A1	10/2005	Deisseroth et al.	
2006/0014248	A1	1/2006	Marshall et al.	
2006/0078994	A1	4/2006	Healey et al.	
2006/0121047	A1	6/2006	Tracey	
2006/0233829	A1	10/2006	Curtiss	
2006/0286074	A1	12/2006	Tang et al.	
2007/0025982	A1	2/2007	Ledbetter et al.	
2007/0082400	A1	4/2007	Healey et al.	
2007/0128183	A1	6/2007	Meinke et al.	
2007/0128223	A1	6/2007	Tang et al.	
2007/0237779	A1	10/2007	Ledbetter et al.	
2008/0004207	A1	1/2008	Tsung et al.	
2008/0069821	A1	3/2008	Yang et al.	
2008/0075728	A1	3/2008	Newman	
2008/0124320	A1	5/2008	O'Keefe	
2008/0305120	A1*	12/2008	Messmer et al. ....	424/185.1
2009/0004194	A1	1/2009	Kedl	
2010/0040608	A1	2/2010	Wahren-Herlenius et al.	
2010/0047231	A1	2/2010	Zabaleta Azpiroz et al.	
2010/0074915	A1*	3/2010	Haynes .....	424/186.1
2010/0112002	A1	5/2010	Lien et al.	
2010/0196419	A1*	8/2010	Compans et al. ....	424/204.1
2010/0233152	A1	9/2010	Bullerdiak	
2010/0291109	A1	11/2010	Kedl	
2010/0292309	A1	11/2010	Vile et al.	
2011/0020318	A1	1/2011	Tracey et al.	

## FOREIGN PATENT DOCUMENTS

WO	WO 96/26735	9/1996
WO	WO 96/40918	12/1996
WO	WO 99/27948	6/1999
WO	WO 99/32138	7/1999
WO	WO 99/59609	11/1999
WO	WO 00/63395	10/2000
WO	WO 00/63405	10/2000
WO	WO 01/42298	6/2001
WO	WO 01/56602	8/2001
WO	WO 02/36769	5/2002
WO	WO 02/092773	11/2002
WO	WO 03/026691	4/2003
WO	WO 03/099340	12/2003
WO	WO 2004/009615	1/2004
WO	WO 2004/046338	6/2004
WO	WO 2004/046345	6/2004
WO	WO 2005/025604	3/2005
WO	WO 2005/035570	4/2005
WO	WO 2005/058950	6/2005
WO	WO 2005/113598	12/2005
WO	WO 2006/012373	2/2006
WO	WO 2006/042177	4/2006
WO	WO 2006/105972	10/2006
WO	WO 2007/011606	1/2007
WO	WO 2007/042583	4/2007
WO	WO 2007/054658	5/2007
WO	WO 2007/056266	5/2007
WO	WO 2007/103048	9/2007
WO	WO 2007/117682	10/2007
WO	WO 2008/036675	3/2008
WO	WO 2008/109825	9/2008
WO	WO 2009/059018	5/2009
WO	WO 2009/059298	5/2009
WO	WO 2011/156619	12/2011

## OTHER PUBLICATIONS

Liu, M. et al., "Display of avian influenza virus nucleoprotein on *Bacillus thuringiensis* cell surface using CTC as a fusion partner," *Applied Genetics and Molecular Biotechnology* (2008) 78:669-676.

Mann, J.F. et al., "Delivery systems: a vaccine strategy for overcoming mucosal tolerance?" *Expert Rev. Vaccines* (2009) 8(1):103-112.

Miga, A. et al., "The role of CD40-CD154 interactions in the regulation of cell mediated immunity," *Immunol. Invest.* (2000) 29:111-114.

Mohamadzadeh, M. et al., "Targeting mucosal dendritic cells with microbial antigens from probiotic lactic acid bacteria," *Expert Rev. Vaccines* (2008) 7(2):163-174 (Abstract).

Moyle, P.M. et al., "Mucosal immunisation: adjuvants and delivery systems," *Curr. Drug Deliv.* (2004) 1(4):385-396 (Abstract).

Mozdzanowska, K. et al., "Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2," *Vaccine* (2003) 21:2616-2626.

Neiryck, S. et al., "A universal influenza A vaccine based on the extracellular domain of the M2 protein," *Nat. Med.* (1999) 5:1157-1163.

Ninomiya, A. et al., "Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus mice," *Vaccine* (2002) 20:3123-3129.

O'Callaghan, D. et al., "Immunogenicity of foreign peptide epitopes expressed in bacterial envelope proteins," *Research in Microbiology* (1990) 141:963-969.

Palese, P. et al., "Influenza vaccines: present and future," *J. Clin. Invest.* (2002) 110:9-13.

Pisetsky, D.S. et al., "High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease," *Arthritis Res. Ther.* (2008) 10(3):209.

Rabsch, W. et al., "Competitive exclusion of *Salmonella enteritidis* by *Salmonella gallinarum* in poultry," *Emerging Inf. Diseases* (2000) 6(5):443-448.

al-Ramadi, B. K. et al., "Induction of innate immunity by IL-2 expressing *Salmonella* confers protection against lethal challenge," *Mol. Immunol.* (2003) 39:763-770.

al-Ramadi, B. K. et al., "Influence of vector-encoded cytokines on anti-*Salmonella* immunity: divergent effects of interleukin-2 and tumor necrosis factor alpha," *Infect. Immun.* (2001) 69:3960-3988.

Rovere-Querini, P. et al., "HMGB1 is an endogenous immune adjuvant released by necrotic cells," *EMBO Rep.* (2004) 5(8):825-830.

Russmann, H. et al., "Delivery of epitopes by the *Salmonella* type III secretion system for vaccine development," *Science* (1998) 281(5376):565-568.

Slepishkin, V.A. et al., "Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein," *Vaccine* (1995) 13:1399-1402.

Su, G.F. et al., "Construction of stable Lamb-Shiga toxin B subunit hybrids: analysis of expression in *Salmonella typhimurium* aroA strains and stimulation of B subunit-specific mucosal and serum antibody responses," *Infect Immun* (1992) 60(8):3345-3359.

Swayne, D.E. et al., "Protection against diverse highly pathogenic H5 avian influenza viruses in chickens immunized with a recombinant fowlpox vaccine containing an H5 avian influenza hemagglutinin gene insert," *Vaccine* (2000) 18:1088-1095.

Swayne, D.E., "Vaccines for List A poultry diseases: emphasis on avian influenza," *Dev. Biol.* (2003) 114:201-212.

Tang, M. et al., "Recombinant adenovirus encoding the HA gene from swine H3N2 influenza virus partially protects mice from challenge with heterologous virus: A/HK/1/68 (H3N2)," *Arch. Virol.* (2002) 147:2125-2141.

Tompkins, S.M. et al., "Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1," *Emerging Infectious Diseases* (2007) 13(3):426-435.

Tregaskes, C.A. et al., "Conservation of biological properties of the CD40 ligand, CD154 in a non-mammalian vertebrate," *Dev. Comp. Immunol.* (2005) 29:361-374.

Tumpey, T.M. et al., "Comparative susceptibility of chickens and turkeys to avian influenza A H7N2 virus infection and protective efficacy of a commercial avian influenza H7N2 virus vaccine," *Avian Dis.* (2004) 48(1):167-176.

Ulloa, L. et al., "High-mobility group box 1 (HMGB1) protein: friend and foe," *Cytokine Growth Factor Rev.* (2006) 17(3):189-201.

Vega, M.L. et al., "A *Salmonella typhi* OmpC fusion protein expressing the CD154 Trp140-Ser149 amino acid strand binds CD40 and activates a lymphoma B-cell line," *Immunol.* (2003) 110:206-216.

(56)

## References Cited

## OTHER PUBLICATIONS

- Verjans, G.M. et al., "Intracellular processing and presentation of T cell epitopes, expressed by recombinant *Escherichia coli* and *Salmonella typhimurium*, to human T cells," *Eur J Immunol* (1995) 25(2):405-410.
- Vierira-Pinto, M. et al., "Occurrence of *Salmonella* in the ileum, ileocolic lymph nodes, tonsils, mandibular lymph nodes and carcasses of pigs slaughtered for consumption," *J Vet Med B Infection Dis Vet Public Health* (2005) 52(10):476-481.
- Wang, J. et al., "Immunogenicity of viral B-cell epitopes inserted into two surface loops of the *Escherichia coli* K12 LamB protein and expressed in an attenuated aroA strain of *Salmonella typhimurium*," *Vaccine* (1999) 17(1):1-12.
- Xu, Y. et al., "The role of CD40-CD154 interaction in cell immunoregulation," *J. Biomed. Sci.* (2004) 11:426-438.
- Zebedee, S.L. et al., "Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions," *J. Virol.* (1988) 62:2762-2772.
- Zharikova, D. et al., "Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2," *J. Virol.* (2005) 79:6644-6654.
- Zou, P. et al., "The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection," *Int. Immunopharmacol.* (2005) 5:631-635.
- International Search Report and Written Opinion of the International Searching Authority for Application No. PCT/US07/78785 dated Sep. 29, 2008 (11 pages).
- International Search Report and Written Opinion for Application No. PCT/US08/81813 dated May 12, 2009 (13 pages).
- International Search Report and Written Opinion for Application No. PCT/US08/082254 dated Jun. 17, 2009 (12 pages).
- International Search Report and Written Opinion of the International Searching Authority for Application No. PCT/US11/22062 dated Mar. 29, 2011 (11 pages).
- International Search Report and Written Opinion for Application No. PCT/US2011/039832 dated Nov. 23, 2011 (23 pages).
- Agterberg, M. et al., "Outer membrane protein PhoE as a carrier for the exposure of foreign antigenic determinants at the bacterial cell surface," *Antonie Van Leeuwenhoek* (1991) 59(4):249-262.
- Andersson, U. et al., "HMGB1 is a therapeutic target for sterile inflammation and infection," *Annu. Rev. Immunol.* (2011) 29:139-162.
- Babu, U., et al., "*Salmonella enteritidis* clearance and immune responses in chickens following *Salmonella* vaccination and challenge," *Vet. Immunol. Immunopathol.* (2004) 101:251-257.
- Barr, T.A. et al., "A potent adjuvant effect of CD40 antibody attached to antigen," *Immunology* (2003) 109:87-92.
- Barrow, P. A., et al., "Reduction in faecal excretion of *Salmonella typhimurium* strain F98 in chickens vaccinated with live and killed *S. typhimurium* organisms," *Epidemiol. Infect.* (1990) 104:413-426.
- Black, R.A. et al., "Antibody response to the M2 protein of influenza A virus expressed in insect cells," *J. Gen. Virol.* (1993) 74(Pt.1):143-146.
- Blomfield, I.C. et al., "Allelic exchange in *Escherichia coli* using the *Bacillus subtilis* sacB gene and a temperature-sensitive pSC101 replicon," *Mol Microbiol* (1991) 5(6):1447-1457.
- Capua, I. et al., "The challenge of avian influenza to the veterinary community," *Avian Pathol.* (2006) 35:189-205.
- Capua, I. et al., "Vaccination for avian influenza in Asia," *Vaccine* (2004) 22:4137-4138.
- Capua, I. et al., "Control of avian influenza in poultry," *Emerg. Infect. Dis.* (2006) 12:1319-1324.
- Charbit, A. et al., "Probing the topology of a bacterial membrane protein by genetic insertion of a foreign epitope; expression at the cell surface," *EMBO J* (1986) 5(11):3029-3037.
- Charbit, A. et al., "Versatility of a vector for expressing foreign polypeptides at the surface of gram-negative bacteria," *Gene* (1988) 70(1):181-189.
- Chatfield et al., "The development of oral vaccines based on live attenuated *Salmonella* strains," *FEMS Immunol. Med. Microbiol.* (1993) 7:1-7.
- Cole, K. et al., "Evaluation of a novel recombinant *Salmonella* vaccine vector for avian influenza," *Poultry Science* (2007) 86(Supp. 1):585-586.
- Cox, M.M. et al., "Scarless and site-directed mutagenesis in *Salmonella enteritidis* chromosome," *BMC Biotech.* (2007) 7(59):10 pages.
- Crawford, J. et al., "Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes," *Vaccine* (1999) 17:2265-2274.
- De Filette, M. et al., "The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection," *Vaccine* (2006) 24:544-551.
- De Filette, M. et al., "Universal influenza A vaccine: Optimization of M2-based constructs," *Virology* (2005) 337:149-161.
- De Filette, M. et al., "Improved design and intranasal delivery of an M2e-based human influenza A vaccine," *Vaccine* (2006) 24:6597-6601.
- Dumitriu, I.E. et al., "HMGB1: guiding immunity from within," *Trends Immunol.* (2005) 26(7):381-387.
- Ernst, W.A. et al., "Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines," *Vaccine* (2006) 24:5158-5168.
- Fan, J. et al., "Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets and rhesus monkeys," *Vaccine* (2004) 22:2993-3003.
- Farnell, M.B. et al., "Upregulation of oxidative burst and degranulation in chicken heterophils stimulated with probiotic bacteria," *Poult. Sci.* (2006) 85:1900-1906.
- Fecteau, J.F. et al., "CD40 Stimulation of Human Peripheral B Lymphocytes: Distinct Response from Naïve and Memory Cells," *J Immunol* (2003) 171:4621-4629.
- Fiers, W. et al., "A universal human influenza A vaccine," *Virus Research* (2004) 103:173-176.
- Frace, A.M. et al., "Modified M2 proteins produce heterotypic immunity against influenza A virus," *Vaccine* (1999) 17:2237-2244.
- Gao, W. et al., "Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization," *J. Virol.* (2006) 80:1959-1964.
- Gares, S.L. et al., "Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks," *Clin. Vaccine Immun.* (2006) 13:958-965.
- Gast, R.K. et al., "The relationship between the magnitude of the specific antibody response to experimental *Salmonella enteritidis* infection in laying hens and their production of contaminated eggs," *Avian Diseases* (2001) 45:425-431.
- Grangette, C. et al., "Protection against tetanus toxin after intragastric administration of two recombinant lactic acid bacteria: Impact and strain viability and in vivo persistence," *Vaccine* (2002) 20:3304-3309.
- Grewal, I.S. et al., "CD40 and CD154 in cell-mediated immunity," *Annu. Rev. Immunology.* (1998) 16:111-135.
- Harcourt, J.L. et al., "CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice," *Vaccine* (2003) 21(21-22):2964-2979.
- Hayes, L.J. et al., "*Chlamydia trachomatis* major outer membrane protein epitopes expressed as fusions with LamB in an attenuated aro A strain of *Salmonella typhimurium*; their application as potential immunogens," *J. of General Microbiology* (1991) 137:1557-1564.
- Holmgren, J. et al., "Mucosal immunity: implications for vaccine development," *Immunobiol.* (1992) 184:157-179.
- Husseiny, M.L. et al., "Rapid method for the construction of *Salmonella enterica* serovar typhimurium vaccine carrier strains," *Infect. Immun.* (2005) 73(3):1598-1605.
- Kaiser, J., "A one-size-fits-all flu vaccine?," *Science* (2006) 312:380-382.
- Katz, J.M. et al., "Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic *Escherichia coli* for oral administration of inactivated influenza virus vaccine," *J. Infect. Dis.* (1997) 175:352-363.

(56)

**References Cited**

## OTHER PUBLICATIONS

Kimura, R. et al., "Enhancement of antibody response by high mobility group box protein-1-based DNA immunization," *J. of Immunol. Methods* (2010) 361:21-30.

Koch, F. et al., "High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10," *J. Exp. Med.* (1996) 184:741-746.

Kodihalli, S. et al., "Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin," *J. Virol.* (1997) 71:3391-3396.

Kotton, C.N. et al., "Enteric pathogens as vaccine vectors for foreign antigen delivery," *Infect. Immun.* (2004) 72:5535-5547.

Kwon, Y.M. et al., "*Salmonella*-based vaccines for infectious disease," *Expert Review of Vaccines* (2007) 6(2):147-152.

Lavelle, E.C. et al., "Delivery systems and adjuvants for oral vaccines," *Expert Opin. Drug Deliv.* (2006) 3(6):747-762.

Layton, S.L., et al., "Vaccination of chickens with recombinant *Salmonella* expressing M2e and CD154 epitopes increases protection and decreases viral shedding after low pathogenic avian influenza challenge," *Poultry Science* (2009) 88(11):2244-2252.

Lee, J. et al., "Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on *Lactobacillus casei* induces neutralizing antibodies in mice," *J. Virol.* (2006) 80:4079-4087.

Lee, J.S. et al., "Surface-displayed viral antigens on *Salmonella* carrier vaccine," *Nat. Biotechnol.* (2000) 18:645-648.

Li, W., "Synergistic antibody induction by antigen-CD40 ligand fusion protein as improved immunogen," *Immunology* (2005) 115(2):215-222.

Liu, W. et al., "Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge," *Immunol. Lett.* (2004) 93:131-136.

Manoj, S. et al., "Targeting with Bovine CD154 enhances humoral immune responses induced by a DNA vaccine in sheep," (2003) *Journal of Immunology* 170:989-996.

Mauriello, E.M.F. et al., "Display of heterologous antigens on the *Bacillus subtilis* spore coat using CotC as a fusion partner," (2004) *Vaccine* 22(9-10):1177-1187.

Nakajima, A. et al., "Antitumor effect of CD40 ligand: Elicitation of local and systemic antitumor responses by IL-12 and B7," (1998) *Journal of Immunology* 161:1901-1907.

Ochoa-Reparaz, J. et al., "Humoral immune response in hens naturally infected with *Salmonella enteritidis* against outer membrane proteins and other surface structural antigens," (2004) *Vet. Res.* 35:291-298.

Saenz, R. et al., "HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen," (2010) *Vaccine* 28(47):7556-7562.

\* cited by examiner




Fig. 1




Fig. 2




Fig.3






Fig.4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9

1

## VACCINE VECTORS AND METHODS OF ENHANCING IMMUNE RESPONSES

### CROSS-REFERENCE TO RELATED APPLICATIONS

This patent application is a national stage filing under 35 U.S.C. §371 of International Application No. PCT/US2011/022062, filed Jan. 21, 2011, which claims the benefit of priority of U.S. Provisional Patent Application No. 61/297,098, filed Jan. 21, 2010, both of which are incorporated herein by reference in their entirety.

### INTRODUCTION

Vaccines are used to initiate an adaptive immune response against antigens, in particular antigens from pathogens, tumor cells or the like, in order to ameliorate or prevent disease. Synthetic peptides or killed or attenuated microorganism vaccines are often effective at stimulating a robust immune response that is fully protective. In some cases these vaccines are not protective or only partially protective and other strategies must be used to develop protective vaccines. Attenuated microorganism based vaccines also are associated with risks of gene transfer or mutation repair and may pose risks to immunocompromised individuals. Development of new vaccines that are safe and effective at stimulating lasting protective immune responses is needed.

Influenza virus infection, particularly avian influenza H5N1, presents a mounting health and economic concern. Evidence clearly indicates that H5N1 is continuing to circulate between susceptible birds and swine in widening regions of the world. Many scientists believe that if left unchecked, the current H5N1 avian influenza will mutate to allow for human to human transmission and cause a world-wide pandemic. With a mortality rate of over 50%, such an outbreak would be devastating. Regardless of the ability of the virus to cause human disease, avian influenza H5N1 is already threatening to have a huge economic impact due to the eradication of poultry flocks in affected areas. Therefore, development of a vaccine to protect humans, poultry, swine and other domesticated animals from H5N1 influenza is needed. An influenza vaccine that is capable of protecting against H5N1 as well as other influenza viruses, such as H1N1, would be optimal.

### SUMMARY

Vaccine vectors and methods of stimulating an immune response and methods of reducing morbidity associated with Influenza infection are provided herein. In one aspect, a vaccine vector including an antigenic polypeptide and an HMGB1 polypeptide or a functional fragment thereof is provided. At least a portion of the antigenic polypeptide and the HMGB1 polypeptide are present on the surface of the vaccine vector. The vaccine vector may include a first polynucleotide encoding the antigenic polypeptide and a second polynucleotide encoding the HMGB1 polypeptide. The HMGB1 polypeptide and the antigenic polypeptide may be linked, such as in a fusion protein. The HMGB1 polypeptide and the antigenic polypeptide may both be inserted within an external loop of a transmembrane protein.

In another aspect, a composition comprising the vaccine vector and a pharmaceutically acceptable carrier is provided. The pharmaceutically acceptable carrier may be acceptable for oral or nasal use. The vaccine vector may be incapable of replication.

2

In yet another aspect, a *Bacillus* spp. vaccine vector is provided. The vaccine vector includes a first polynucleotide sequence encoding an antigenic polypeptide expressed on the surface of the vaccine vector and a second polynucleotide sequence encoding an immunostimulatory polypeptide expressed on the surface of the vaccine vector. The antigenic polypeptide may be an Influenza M2e polypeptide, an Influenza HA polypeptide, or an Influenza NP polypeptide or a combination thereof. The immunostimulatory polypeptide may be a CD154 polypeptide or a HMGB1 polypeptide or a combination thereof. The immunostimulatory polypeptide and the antigenic polypeptide may be linked, such as in a fusion protein and may be inserted with an external loop of a transmembrane protein.

In still another aspect, methods of enhancing an immune response in a subject are provided. In the method, the vaccine vectors or compositions provided herein are administered to the subject in an amount effective to enhance the immune response of the subject to the antigenic polypeptide. Suitably, the vaccine vector is administered orally or intranasally.

In a further aspect, methods of enhancing the immune response in a subject by administering a *Bacillus* spp. vaccine vector as described herein are provided. The vaccine vector includes a first polynucleotide sequence encoding an antigenic polypeptide expressed on the surface of the vaccine vector and a second polynucleotide sequence encoding an immunostimulatory polypeptide expressed on the surface of the vaccine vector. The antigenic polypeptide may be an Influenza M2e polypeptide, an Influenza HA polypeptide, an Influenza NP polypeptide or a combination thereof. The immunostimulatory polypeptide may be a CD154 polypeptide, a HMGB1 polypeptide or a combination thereof.

In a still further aspect, methods of reducing influenza related morbidity in a subject are provided. In the methods, administration of the vaccine vectors or compositions disclosed herein reduces the morbidity associated with a subsequent influenza infection.

### BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a graph showing the S/P (sample to positive control) ratios of the ELISA for M2e specific antibody production by chickens after oral gavage of the indicated dosage of *Bacillus subtilis* vaccine vector expressing the Influenza A epitopes and either HMGB1 or CD154 as compared to chickens vaccinated with saline.

FIG. 2 is a graph showing the S/P ratios of the ELISA for HA LB specific antibody production by chickens after oral gavage of the indicated dosage of *Bacillus subtilis* vaccine vector expressing the Influenza A epitopes and either HMGB1 or CD154 as compared to chickens vaccinated with saline.

FIG. 3 is a graph showing the S/P ratios of the ELISA for HA UA specific antibody production by chickens after oral gavage of the indicated dosage of *Bacillus subtilis* vaccine vector expressing the Influenza A epitopes and either HMGB1 or CD154 as compared to chickens vaccinated with saline.

FIG. 4 is a graph showing the S/P ratios of the ELISA for M2e specific antibody production by chickens after oral gavage of the indicated dosage of live or variously inactivated *Bacillus subtilis* vaccine vectors expressing the Influenza A epitopes and either HMGB1 or CD154 as compared to chickens vaccinated with the *Bacillus* vector alone (BSBB).

FIG. 5 is a graph showing the S/P ratios of the ELISA for HA LB specific antibody production by chickens after oral gavage of the indicated dosage of live or variously inactivated

*Bacillus subtilis* vaccine vectors expressing the Influenza A epitopes and either HMGB1 or CD154 as compared to chickens vaccinated with the *Bacillus* vector alone (BSBB).

FIG. 6 is a graph showing the S/P ratios of the ELISA for HA UA specific antibody production by chickens after oral gavage of the indicated dosage of live or variously inactivated *Bacillus subtilis* vaccine vectors expressing the Influenza A epitopes and either HMGB1 or CD154 as compared to chickens vaccinated with the *Bacillus* vector alone (BSBB).

FIG. 7 is a graph showing the S/P ratios of the ELISA for M2e specific IgG antibody production by chickens after oral gavage of either 10<sup>6</sup> live or the various indicated dosages of formalin inactivated *Bacillus subtilis* vaccine vectors expressing the Influenza A epitopes and HMGB1 as compared to chickens vaccinated with the *Bacillus* vector alone (BSBB).

FIG. 8 is a graph showing the S/P ratios of the ELISA for M2e specific IgA antibody production by chickens vaccinated, either orally or subcutaneously, with 10<sup>6</sup> live, formalin inactivated or formalin inactivated and lyophilized *Bacillus subtilis* vaccine vectors expressing the Influenza A epitopes and HMGB1 as compared to chickens vaccinated with the *Bacillus* vector alone (BSBB).

FIG. 9 is a graph showing the S/P ratios of the ELISA for M2e specific IgA antibody production by chickens vaccinated, either orally or subcutaneously, with 10<sup>6</sup> live, formalin inactivated or formalin inactivated and lyophilized *Bacillus subtilis* vaccine vectors expressing the Influenza A epitopes and HMGB1 as compared to chickens vaccinated with the *Bacillus* vector alone (BSBB).

#### DETAILED DESCRIPTION

Recombinant DNA technologies enable relatively easy manipulation of many bacterial and viral species. Some bacteria and viruses are either naturally or can be selected or engineered to be mildly pathogenic or non-pathogenic, but remain capable of generating a robust immune response. These bacteria and viruses make attractive vaccine vectors for eliciting an immune response to heterologous or foreign antigens. Bacterial or viral vaccine vectors may mimic the natural infection and produce robust and long lasting immunity. Vaccine vectors are often relatively inexpensive to produce and administer. In addition, such vectors can often carry more than one antigen and may provide protection against multiple infectious agents.

Live bacterial or viral vaccine vectors may still pose risks to immunocompromised individuals and require additional regulatory scrutiny. Thus use of vectors that are killed or inactivated or qualify as Generally Regarded As Safe (GRAS) organisms by the Food and Drug Administration (FDA) is desirable. The problem is generating a robust immune response using such vectors. As shown in the Examples, by including HMGB1 (high mobility group box 1) polypeptides on the surface of the vaccine vector we can generate a robust immune response against antigenic polypeptides using a *Bacillus* spp. vector. In fact, the Examples demonstrate that this vector can be inactivated such that it cannot replicate using a variety of methods and still elicit a robust immune response after administration.

Vaccine vectors including an antigenic polypeptide and an HMGB1 polypeptide or a functional fragment thereof are provided herein. At least a portion of the antigenic polypeptide and at least a portion of the HMGB1 polypeptide or functional fragment thereof are present on the surface of the vaccine vector. The vaccine vector may include a first polynucleotide encoding the antigenic polypeptide and a second

polynucleotide encoding the HMGB1 polypeptide. The HMGB1 polypeptide and the antigenic polypeptide may be linked, such as in a fusion protein or may be expressed separately. The HMGB1 polypeptide and the antigenic polypeptide may both be inserted within an external loop of a transmembrane protein.

The vaccine vectors may be bacterial, viral or liposome-based vectors. Potential vaccine vectors include, but are not limited to, *Bacillus* (*Bacillus subtilis*), *Salmonella* (*Salmonella enteritidis*), *Shigella*, *Escherichia* (*E. coli*), *Yersinia*, *Bordetella*, *Lactococcus*, *Streptococcus*, *Vibrio* (*Vibrio cholerae*), *Listeria*, adenovirus, poxvirus, herpesvirus, alphavirus, and adeno-associated virus. Suitably, the vaccine vector is a GRAS organism. The vaccine vector may be inactivated or killed such that it is not capable of replicating. Methods of inactivating or killing bacterial or viral vaccine vectors are known to those of skill in the art and include, but are not limited to methods such as those shown in the Examples, namely formalin inactivation, antibiotic-based inactivation, heat treatment and ethanol treatment.

An antigenic polypeptide is a polypeptide that is capable of being specifically recognized by the adaptive immune system. An antigenic polypeptide includes any polypeptide that is immunogenic. The antigenic polypeptides include, but are not limited to, antigens that are pathogen-related, allergen-related, tumor-related or disease-related. Pathogens include viral, parasitic, fungal and bacterial pathogens as well as protein pathogens such as the prions. The antigenic polypeptides may be full-length proteins or portions thereof. It is well established that immune system recognition of many proteins is based on a relatively small number of amino acids, often referred to as the epitope. Epitopes may be only 8-10 amino acids. Thus, the antigenic polypeptides described herein may be full-length proteins, 8 amino acid long epitopes or any portion between these extremes. In fact the antigenic polypeptide may include more than one epitope from a single pathogen or protein.

Multiple copies of the same epitope or multiple epitopes from different proteins may be included in the vaccine vector. It is envisioned that several epitopes or antigens from the same or different pathogens or diseases may be administered in combination in a single vaccine vector to generate an enhanced immune response against multiple antigens. Recombinant vaccine vectors may encode antigens from multiple pathogenic microorganisms, viruses or tumor associated antigens. Administration or vaccine vectors capable of expressing multiple antigens has the advantage of inducing immunity against two or more diseases at the same time.

The antigenic polypeptide may be an Influenza polypeptide, suitably it is an Influenza H5N1 polypeptide or a polypeptide associated with multiple strains of the Influenza virus such as a polypeptide of the Influenza M2 protein. The ectodomain of the Influenza A virus M2 protein, known as M2e, protrudes from the surface of the virus. The M2e portion of the M2 protein contains about 24 amino acids. The M2e polypeptide varies little from one isolate to the next within Influenza. In fact, only a few naturally occurring mutations in M2e have been isolated from infected humans since the 1918 flu epidemic. In addition, influenza viruses isolated from avian and swine hosts have different, yet still conserved, M2e sequences. For reviews of the M2e polypeptide sequences isolated from human, avian and swine hosts see Liu et al., *Microbes and Infection* 7:171-177 (2005) and Reid et al., *J. Virol.* 76:10717-10723 (2002) each of which are incorporated herein by reference in its entirety. See also SEQ ID NO: 1-4.



5

Suitably the entire M2e polypeptide may be inserted into the vaccine vector or only a portion may be used. In the Examples, an eight amino acid polypeptide (LM2 having amino acid sequence: EVETPIRN, SEQ ID NO:5 or its variant M2eA having amino acid sequence EVETPTRN, SEQ ID NO:6) was incorporated into the vaccine vector and demonstrated to produce an antibody response after administration to chickens. Suitably, the portion of the M2e polypeptide inserted into the vaccine vector is immunogenic. An immunogenic fragment is a peptide or polypeptide capable of eliciting a cellular or humoral immune response. Suitably, an immunogenic fragment of M2e may be the full-length M2e polypeptide, or suitably may be 20 or more amino acids, 15 or more amino acids, 10 or more amino acids or 8 or more amino acids of the full-length sequence.

Other suitable epitopes for inclusion in an Influenza A vaccine vector include, but are not limited to, polypeptides of the hemagglutinin (HA) or the nuclear protein (NP) of Influenza A. For example, the peptides of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10 may be included in a vaccine vector. In the Examples, SEQ ID NO: 7 (HAUA) and SEQ ID NO: 8 (HALB) were incorporated into the vaccine vector and demonstrated to produce an antibody response after administration to chickens. See FIGS. 2-3 and 5-6. In addition, the NP epitopes of SEQ ID NO: 9 (NP54) and SEQ ID NO: 10 (NP 147) were incorporated into the vaccine vector in the examples. One of skill in the art will appreciate that any of these sequences may be used in combination with any other epitope including epitopes derived from other pathogens or antigens.

The HMGB1 (High Mobility Group Box-1) protein was first identified as a DNA-binding protein critical for DNA structure and stability. It is a ubiquitously expressed nuclear protein that binds DNA with no sequence specificity. The protein is highly conserved and found in plants to mammals. The zebrafish, chicken and human HMGB1 amino acid sequences are provided in SEQ ID NO: 30, SEQ ID NO: 18 and SEQ ID NO: 29, respectively. The sequence throughout mammals is highly conserved with 98% amino acid identity and the amino acid changes are conservative. Thus an HMGB1 protein from one species can likely substitute for that from another species functionally. The full-length HMGB1 protein or a portion thereof may be used as the HMGB1 polypeptide in the vaccine vectors described herein. HMGB1 has two DNA binding regions termed A box as shown in SEQ ID NO: 23 and 24 and B box as shown in SEQ ID NO: 25 and 26. See Andersson and Tracey, *Annu. Rev. Immunol.* 2011, 29:139-162, which is incorporated herein by reference in its entirety.

HMGB1 is a mediator of inflammation and serves as a signal of nuclear damage, such as from necrotic cells. HMGB1 can also be actively secreted by cells of the monocyte/macrophage lineage in a process requiring acetylation of the protein, translocation across the nucleus and secretion. Extracellular HMGB1 acts as a potent mediator of inflammation by signaling via the Receptor for Advanced Glycated End-products (RAGE) and via members of the Toll-like Receptor family (TLR), in particular TLR4. The RAGE binding activity has been identified and requires the polypeptide of SEQ ID NO: 27. TLR4 binding requires the cysteine at position 106 of SEQ ID NO: 18, which is found in the B box region of HMGB1.

The inflammatory activities of HMGB1 do not require the full-length protein and functional fragments have been identified. The B box has been shown to be sufficient to mediate the pro-inflammatory effects of HMGB1 and thus SEQ ID NO: 25 and 26 are HMGB1 polypeptides or functional frag-

6

ments thereof within the context of the present invention. In addition, the RAGE binding site and the pro-inflammatory cytokine activity have been mapped to SEQ ID NO: 27 and SEQ ID NO: 28, respectively. Thus, these polypeptides are functional fragments of HMGB1 polypeptides in the context of the present invention.

Those of skill in the art are capable of identifying HMGB1 polypeptides and fragments thereof capable of stimulating pro-inflammatory cytokine activity, using methods such as those in International Publication No. WO02 092004, which is incorporated herein by reference in its entirety. Suitably, the HMGB1 polypeptide includes the RAGE binding domain at amino acids 150-183 of SEQ ID NO:18 (SEQ ID NO: 27 or a homolog thereof) and the pro-inflammatory cytokine activity domain between amino acids 89-109 of SEQ ID NO: 18 (SEQ ID NO: 28 or a homolog thereof). In particular, HMGB1 polypeptides and functional fragments or homologs thereof include polypeptides identical to, or at least 99% identical, at least 98% identical, at least 95% identical, at least 90% identical, at least 85% identical, or at least 80% identical to the HMGB1 polypeptides of SEQ ID NOs: 18 or 23-30.

At least a portion of the antigenic polypeptide and at least a portion of the HMGB1 polypeptide are present on the surface of the vaccine vector. Present on the surface of the vaccine vector includes polypeptides that are comprised within a transmembrane protein, interacting with, covalently or chemically cross-linked to a transmembrane protein, a membrane lipid or membrane anchored carbohydrate. A polypeptide can be comprised within a transmembrane protein by having the amino acids comprising the polypeptide linked via a peptide bond to the N-terminus, C-terminus or anywhere within the transmembrane protein (i.e. inserted between two amino acids of the transmembrane protein or in place of one or more amino acids of the transmembrane protein (i.e. deletion-insertion). Suitably, the polypeptides may be inserted into an external loop of a transmembrane protein. Suitable transmembrane proteins are cotB and lamB, but those of skill in the art will appreciate many suitable transmembrane proteins are available.

Alternatively, the polypeptides may be covalently or chemically linked to proteins, lipids or carbohydrates in the membrane, or capsid if a viral vector is being used through methods available to persons of skill in the art. For example, di-sulfide bonds or biotin—avidin cross-linking could be used to present the antigenic and HMGB1 polypeptides on the surface of a vaccine vector. Suitably, the antigenic polypeptide and the HMGB1 polypeptide are part of a fusion protein. The two polypeptides may be directly linked via a peptide bond or may be separated by a linker or a section of a third protein into which they are inserted.

Polynucleotides encoding the antigenic polypeptide or HMGB1 polypeptide may be inserted into the vaccine vector and expressed to generate the antigenic polypeptide and the HMGB1 polypeptide. The polynucleotides may be inserted into the chromosome of the vaccine vector or encoded on plasmids or other extrachromosomal DNA. Suitably, polynucleotides encoding the antigenic polypeptide and/or the HMGB1 polypeptide may be expressed independently or are inserted into a vaccine vector polynucleotide that is expressed. Suitably, the vaccine vector polynucleotide encodes a polypeptide expressed on the surface of the vaccine vector such as a transmembrane protein. The polynucleotide encoding the antigenic polypeptide and/or the HMGB1 polypeptide may be inserted into the vaccine vector polynucleotide sequence to allow expression of the antigenic polypeptide and/or the HMGB1 polypeptide on the surface of the vector. For example, the polynucleotide encoding the

antigenic polypeptide and the HMGB1 polypeptide may be inserted in frame into a bacterial polynucleotide in a region encoding an external loop region of a transmembrane protein such that the bacterial polynucleotide sequence remains in frame. See Example 1.

Alternatively, the polynucleotide encoding the antigenic polypeptide and/or the HMGB1 polypeptide may be inserted into a secreted polypeptide which is displayed or presented on the surface of the vaccine vector through association with a protein, lipid or carbohydrate on the surface of the vaccine vector. Those of skill in the art will appreciate that the polynucleotide encoding the antigenic polypeptide and/or the HMGB1 polypeptide could be inserted in a wide variety of vaccine vector polynucleotides to provide expression and presentation of the antigenic polypeptide and/or the HMGB1 polypeptide to the immune cells of a subject treated with the vaccine vector. In the Examples, several Influenza epitopes including an M2e epitope, a HA epitope and a NP epitope were expressed from a plasmid for vegetative expression in *Bacillus subtilis*. The resulting recombinant bacteria express the inserted epitopes as demonstrated by the immune response shown in FIGS. 1-6.

In the Examples, the vaccine vectors have the antigenic polypeptides (M2e, HA and NP polypeptides) and the immunostimulatory polypeptide (either CD154 or HMGB1) encoded on the same polynucleotide and in frame with each other. In alternative embodiments, the immunostimulatory polypeptide and the antigenic polypeptide may be encoded by distinct polynucleotides. Those of skill in the art will appreciate that a variety of methods may be used to obtain expression of the antigenic polypeptide and the polypeptide on the surface of the vaccine vector. Such methods are known to those skilled in the art.

Compositions comprising the vaccine vector and a pharmaceutically acceptable carrier are also provided. A pharmaceutically acceptable carrier is any carrier suitable for in vivo administration. Suitably, the pharmaceutically acceptable carrier is acceptable for oral, nasal or mucosal delivery. The pharmaceutically acceptable carrier may include water, buffered solutions, glucose solutions or bacterial culture fluids. Additional components of the compositions may suitably include excipients such as stabilizers, preservatives, diluents, emulsifiers and lubricants. Examples of pharmaceutically acceptable carriers or diluents include stabilizers such as carbohydrates (e.g., sorbitol, mannitol, starch, sucrose, glucose, dextran), proteins such as albumin or casein, protein-containing agents such as bovine serum or skimmed milk and buffers (e.g., phosphate buffer). Especially when such stabilizers are added to the compositions, the composition is suitable for freeze-drying or spray-drying. The vaccine vector in the compositions may not be capable of replication, suitably the vaccine vector is inactivated or killed prior to addition to the composition.

The compositions described herein may be used to enhance an immune response such as an antibody response to the antigenic polypeptide. The compositions containing Influenza polypeptides may also be used to decrease the morbidity associated with subsequent Influenza infection. The compositions may prevent Influenza from causing disease or any associated morbidity in a subject to which the compositions or vaccine vectors described herein were administered. The compositions and vaccine vectors described herein may reduce the severity of subsequent disease by decreasing the length of disease, decreasing the morbidity or mortality associated with the disease or reducing the likelihood of contracting the disease. The morbidity or mortality associated with the disease after administration of the vaccine vectors

described herein may be reduced by 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or even 100% as compared to similar subjects not provided the vaccine vector.

Methods of enhancing immune responses in a subject by administering a vaccine vector are also provided. The vaccine vector may contain a HMGB1 polypeptide capable of stimulating the immune response to the vaccine vector and its associated antigenic polypeptide. The vaccine vector comprising a polypeptide of HMGB1 is administered to a subject in an amount effective to enhance the immune response of the subject to the vaccine and in particular to the antigenic polypeptide. Suitably, the vaccine vector contains a polynucleotide encoding a polypeptide including amino acids 150-183 and 89-109 of the HMGB1 polypeptide (SEQ ID NO: 18) or a homolog thereof. In the Examples, a 190 amino acid polypeptide of HMGB1 was used. Suitably, the polynucleotide encodes a HMGB1 polypeptide from the same species as the subject. Heterologous combinations of HMGB1 polypeptides and subjects (i.e. a human HMGB1 polypeptide for use in a chicken vaccine) may be useful in the methods of the invention because HMGB1 is highly conserved through a wide number of species. The HMGB1 polypeptide may be used to enhance the immune response in the subject to any foreign antigen or antigenic polypeptide present in or on the vaccine vector. One of skill in the art will appreciate that the HMGB1 polypeptide could be used to enhance the immune response to more than one antigenic polypeptide present in a vaccine vector. The polypeptide from HMGB1 stimulates an immune response at least in part by activating dendritic cells and macrophages and thus stimulating production of cytokines such as IL-1, IL-6, IFN- $\gamma$  and TNF- $\alpha$ . In the Examples, a polypeptide of HMGB1 was expressed on the surface of the vaccine vector.

In addition, methods of enhancing an immune response against influenza A and methods of reducing morbidity associated with subsequent Influenza A infection are disclosed. Briefly, the methods comprise administering to a subject a vaccine vector comprising an Influenza A epitope (an antigenic polypeptide of Influenza) capable of eliciting an immune response in an amount effective to elicit the immune response. The Influenza A epitope may be a M2e polypeptide, an HA polypeptide or a NP polypeptide or another influenza polypeptide as discussed above. The insertion of the antigenic polypeptides into the vaccine vector may be accomplished in a variety of ways known to those of skill in the art; including but not limited to the scarless site-directed mutation system described in International Patent Publication No. WO 2008/036675. The bacterium may also be engineered to express Influenza polypeptides in conjunction with polynucleotides capable of enhancing the immune response as discussed above. In particular, a polypeptide of CD154 or HMGB1 may be expressed by the vaccine vector to enhance the immune response of the subject to the influenza polypeptides. The Examples demonstrate production of a robust IgA and IgG response to vaccination in chickens. We expect that such a robust response will be protective against or at least reduce the morbidity associated with subsequent infection or challenge with the source of the antigenic polypeptide (Influenza virus in the Examples).

The compositions may be administered by a variety of means including, but not limited to, orally, intranasally, and mucosally. For example, the compositions or vaccine vectors may be delivered by aerosol, by spraying, by addition to food or water, by oral gavage, or via eye drops. In some embodiments, the compositions are administered by injection such as intradermally, parenterally, subcutaneously, intraperito-

neally, intravenously, intracranially, or intramuscularly. For chickens or other poultry, the compositions may be administered in ovo.

Subjects include, but are not limited to, a vertebrate, suitably a mammal, suitably a human, cows, cats, dogs, pigs, or birds, suitably poultry such as chickens. Other animal models of infection may also be used. Enhancing an immune response includes, but is not limited to, inducing a therapeutic or prophylactic effect that is mediated by the immune system of the subject. Specifically, enhancing an immune response may include enhanced production of antibodies, such as demonstrated in FIGS. 1-3, enhanced class switching of antibody heavy chains such as production of IgA as shown in FIG. 8, maturation of antigen presenting cells, stimulation of helper T cells, stimulation of cytolytic T cells or induction of T and B cell memory.

The useful dosage to be administered will vary depending on the age, weight and species of the subject, the mode and route of administration and the type of pathogen or disease against which an immune response is sought. The composition may be administered in any dose of vaccine vector sufficient to evoke an immune response. It is envisioned that doses ranging from  $10^3$  to  $10^{19}$  vector copies (i.e. plaque forming or colony forming units), from  $10^4$  to  $10^9$  vector copies, or from  $10^5$  to  $10^7$  vector copies are suitable.

The composition may be administered only once or may be administered two or more times to increase the immune response. For example, the composition may be administered two or more times separated by one week, two weeks, or by three weeks, one month, two months, three months, six months or more. The bacteria may be viable prior to administration, but in some embodiments the bacteria may be killed or inactivated prior to administration. In some embodiments, the bacteria may be able to replicate in the subject, while in other embodiments the bacteria may not be capable of replicating in the subject. As shown in the Examples, bacterial vaccine vectors may be inactivated prior to administration using formalin, ethanol, heat or antibiotics. One skilled in the art would appreciate other means of inactivating vaccine vectors could be used as well.

A *Bacillus* spp. vaccine vector is also provided herein. The *Bacillus* vaccine vector includes a first polynucleotide sequence encoding an antigenic polypeptide and a second polynucleotide sequence encoding an immunostimulatory polypeptide. The antigenic polypeptide and the immunostimulatory polypeptide are present on the surface of the *Bacillus* vaccine vector as described above. The antigenic polypeptide is an Influenza polypeptide as described above and the immunostimulatory polypeptide is a HMGB1 polypeptide as described above or a CD154 polypeptide.

Polynucleotides encoding immunostimulatory polypeptides that are homologous to proteins of the subject and capable of stimulating the immune system to respond to the antigenic polypeptide may also be inserted into a vaccine vector. As described in more detail in the Examples, a vaccine vector may include a CD154 polypeptide that is capable of binding CD40 in the subject and stimulating the subject to respond to the vaccine vector and its associated antigenic polypeptide, similar to HMGB1 described above. The *Bacillus* vaccine vector may include a HMGB1 polypeptide, a CD154 polypeptide or a combination thereof. As described above, polynucleotides encoding these polypeptides may be inserted into the chromosome of the vaccine vector or maintained extrachromosomally. One of skill in the art will appreciate that these polypeptides can be inserted in a variety of polypeptides of the vaccine vector and expressed in different parts of the vaccine vector or may be secreted.

The polynucleotide encoding an immunostimulatory polypeptide capable of enhancing the immune response to an antigenic polypeptide may also encode the antigenic polypeptide. The polynucleotide encoding an immunostimulatory polypeptide may be linked to the polynucleotide encoding the antigenic polypeptide, such that in the vaccine vector the immunostimulatory polypeptide and the antigenic polypeptide are encoded by the same polynucleotide. In the Examples, a polynucleotide encoding a polypeptide of CD154, which is capable of binding to CD40, or HMGB1 also encodes an M2e epitope, an HA epitope and a NP epitope of Influenza A. See SEQ ID NOs: 19-22. In the Examples, the polynucleotide encoding the Influenza epitopes and the polynucleotide encoding the immunostimulatory polypeptide are both expressed from a plasmid for vegetative cell expression. In some embodiments, the polynucleotides are inserted in the *cotB* gene or another gene encoding a protein expressed on the surface of spores. Those of skill in the art will appreciate that bacterial polynucleotides encoding other transmembrane proteins may also be used.

As discussed above, a polynucleotide encoding an immunostimulatory polypeptide homologous to a protein of the subject that is capable of enhancing the immune response to the epitope may be included in the vaccine vector. In the Examples, a *Bacillus* vaccine vector including a polynucleotide encoding either a CD154 polypeptide capable of binding to CD40 or a polypeptide encoding HMGB1 were demonstrated to enhance the immune response to the M2e epitope and to two distinct HA epitopes as measured by increased antibody production in response to vaccination.

Suitably, the CD154 polypeptide is fewer than 50 amino acids long, more suitably fewer than 40, fewer than 30 or fewer than 20 amino acids in length. The polypeptide may be between 10 and 15 amino acids, between 10 and 20 amino acids or between 10 and 25 amino acids in length. The CD154 sequence and CD40 binding region are not highly conserved among the various species. The CD154 sequences of chicken and human are provided in SEQ ID NO: 11 and SEQ ID NO: 12, respectively.

The CD40 binding regions of CD154 have been determined for a number of species, including human, chicken, duck, mouse and cattle and are shown in SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, respectively. Although there is variability in the sequences in the CD40 binding region between species, the Examples below indicate that the human CD154 polypeptide was able to enhance the immune response in chickens. Therefore, one may practice the invention using species specific CD154 polypeptides or a heterologous CD 154 polypeptide. In particular, CD154 polypeptides and functional fragments or homologs thereof include polypeptides identical to, or at least 99% identical, at least 98% identical, at least 95% identical, at least 90% identical, at least 85% identical, or at least 80% identical to the CD154 polypeptides of SEQ ID NOs: 11-17.

The *Bacillus* vaccine vector described herein may be used in the methods of enhancing an immune response and the methods of reducing Influenza morbidity in a subject as described above. The *Bacillus* vaccine vector may be used to make compositions for administration to subjects such as those described above as well.

Heterologous polynucleotides encoding antigenic polypeptides can be inserted in the bacterial genome at any non-essential site or alternatively may be carried on a plasmid using methods well known in the art. One suitable site for insertion of polynucleotides is within external portions of transmembrane proteins or coupled to sequences which target the heterologous polynucleotide for secretory pathways.

Examples of a suitable transmembrane protein for insertion of polynucleotides are the cotB gene of *Bacillus* and the lamB gene of *Salmonella*.

Heterologous polynucleotides include, but are not limited to, polynucleotides encoding antigens selected from pathogenic microorganisms or viruses other than the vaccine vector. Such polynucleotides may be derived from pathogenic viruses such as influenza (e.g., M2e, hemagglutinin, or neuraminidase), herpesviruses (e.g., the genes encoding the structural proteins of herpesviruses), retroviruses (e.g., the gp160 envelope protein), adenoviruses, paramyxoviruses, coronaviruses and the like. Heterologous polynucleotides can also be obtained from pathogenic bacteria, e.g., genes encoding bacterial proteins such as toxins, and outer membrane proteins. Further, heterologous polynucleotides from parasites, such as *Eimeria* are attractive candidates for use in a vector vaccine.

Additional immunostimulatory polypeptides involved in triggering the immune system may also be included in the vaccine vectors described herein. The polynucleotides may encode immune system molecules known for their stimulatory effects, such as an interleukin, Tumor Necrosis Factor or an interferon, or another polynucleotide involved in immune-regulation.

The following examples are meant only to be illustrative and are not meant as limitations on the scope of the invention or of the appended claims.

## EXAMPLES

### Example 1

#### Construction of HA/NP/M2e/cCD154 and HA/NP/M2e/HMGB1 *Bacillus* Vectors

##### Strains and Culture Conditions

All plasmids were first maintained in TOP 10 *E. coli* cells (Invitrogen, Carlsbad, Calif., USA) unless described otherwise. *Bacillus* spp. was used for introduction of mutations (*Bacillus subtilis*, Poultry Health Laboratory strain designated as NP 122). Bacteria carrying plasmid pDGIEF and pHT10 were grown at 37° C.

Luria-Bertani (LB) media was used for routine growth of cells, and SOC media (Invitrogen, Carlsbad, Calif., USA) was used for phenotypic expression after electroporation. When appropriate, the following were added to the media:

Isopropyl-β-D-thiogalactopyranoside (IPTG) at 1 mM, ampicillin (Amp) at 100 μg/ml, spectinomycin (SP) at 100 μg/ml, and chloramphenicol (Cm) at 5 μg/ml.

##### Plasmids

Plasmids pDGIEF (*Bacillus* Genetic Stock Center, Columbus, Ohio) and pHT10 used for the present study were described previously (Zhang et al., Nuc. Acids Research

2006, 34 (9):1-8 and Nguyen et al., Curr. Micro. 2007, 55:89-93). Plasmid pDGIEF served as a template for amplification of the mazF gene which was used as the counter-selectable marker during *Bacillus* chromosomal manipulation. Plasmid pHT10 was used to code for and produce the heterologous epitope sequences for Avian Influenza within *Bacillus* spp. This plasmid contains a CM resistance gene, is induced by the addition of 1 mM IPTG, and is maintained within *Bacillus* at 37° C.

##### Production of Heterologous Proteins for Vegetative Cell Expression:

Plasmid pHT10 purchased from MoBioTec/Boca Scientific, Boca Raton, Fla. (Nguyen et al., 2007) was transformed at the multiple cloning site by addition of a *Bacillus subtilis* codon optimized insertion sequence. DNA sequencing was done to confirm correct sequence insertion. The newly modified plasmid was then transformed into *Bacillus*. Briefly, *Bacillus* cultures were grown overnight at 37° C. in HS media (Spizizen's medium supplemented with 0.5% glucose, 50 μg/ml DL-tryptophan, 50 μg/ml uracil, 0.02% casein hydrolysate, 0.1% yeast extract, 8 μg/ml arginine, 0.4 μg/ml histidine, 1 mM MgSO<sub>4</sub>). The overnight culture (1 ml) was used to inoculate 20 ml LS medium (Spizizen's medium supplemented with 0.5% glucose, 5 μg/ml DL-tryptophane, 5 μg/ml uracil, 0.01% casein hydrolysate, 0.1% yeast extract, 1 mM MgSO<sub>4</sub>, 2.5 mM MgCl<sub>2</sub>, 0.5 mM CaCl<sub>2</sub>) and incubated with shaking for 3-4 hours at 30° C. To 1 ml of the resulting LS culture 10 μl of 0.1 M EGTA was added and incubated at room temperature for 5 minutes. Then 1-2 μg plasmid DNA was added, shaken for 2 hours at 37° C., and plated on LB plates with selective antibiotics. These transformed *Bacillus* spp. now produce heterologous epitope sequences from AI when induced with 1 mM IPTG.

##### PCR

All primers used for PCR are listed in Table 1. Typical PCR conditions consisted of approximately 0.1 μg of purified genomic, plasmid or PCR-generated DNA (Qiagen, Valencia, Calif., USA), 1×Pfu polymerase buffer, 5 U Pfu polymerase (Stratagene La Jolla, Calif., USA), 1 mM dNTPs (GE Healthcare Bio-Sciences Corp., Piscataway, N.J.), 1.2 μM of each primer in a total volume of 50 μL. The DNA engine thermal cycler (Bio-Rad, Hercules, Calif., USA) was used with the following amplification conditions: 94° C. for 2 minutes; 30 cycles of 94° C. for 30 sec, 58° C. for 60 sec, 72° C. for 90 sec per 1 kb; and 72° C. for 10 minutes for final extension. Each PCR product was gel purified (Qiagen, Valencia, Calif., USA) and either eluted in 25 μL EB buffer for preparation of templates used in overlapping extension PCR or in 50 μL EB buffer, ethanol precipitated and suspended in 5 μL of ddH<sub>2</sub>O for electroporation into *Bacillus* spp.

TABLE 1

Primer sequences used to generate the vaccine vector		
Primer	Amplified Region	Primer Sequence (SEQ ID NO: )
mazF for	MazF gene	5' ctaaaaatcttcagatgatcaatcctcctcactgcccgctttccagtcgggaaa3' (SEQ ID NO: 31)
mazF rev	MazF gene	5'tgaacgtgacgaacgaccagatttcccctatgcaagggtttat3' (SEQ ID NO: 32)
CotB up for	Cot B up	5' gaaatgctcgatgctgatga 3' (SEQ ID NO: 33)

TABLE 1-continued

Primer sequences used to generate the vaccine vector		
Primer	Amplified Region	Primer Sequence (SEQ ID NO: )
Cot B up rev	Cot B up	5'ggatgattgatcatctgaagatttag3' (SEQ ID NO: 34)
Cot B dn for	Cot B down	5'aaatctggctgctcgcgtcacttca3' (SEQ ID. NO: 35)
Cot B dn rev	Cot B down	5' ttacgtttccagtgatagtctatcg3' (SEQ ID NO: 36)
BS/AI/HMGB1 for	BS/AI/HMGB1 CotB up	5'aaccattctttcaattgtaattgaaatgaaatcagctgctgatgatgacagttcttcataatcattaaaatc gccggatagcacagatcatttgcggattgctgatgatgaatccatgctgttctaaccagtgctctgttc ttgatatgt <i>ggatgattgatcatctgaagatttag3'</i> (SEQ ID NO: 37)
BS/AI/HMGB1 rev	BS/AI/HMGB1 CotB down	5'ttacaattgaaagaatggttctgctcatcatcatcactgctgcaagaattaatcattttgaaaaaattcaatcat catcagaagttgaaacaccgattagaattcatcatcctggatgacaacatcatatgcaccgacatcatcatca tcagaagttgaaacaccgattagaataaattctggtcgttcgctcacgttca3' (SEQ ID NO: 38)
BS/AI/CD154 for	BS/AI/CD154 CotB up	5'ttcaaatgattaattcttgacagcagtgatgatgatgacagaaccattctttcaattgtaattgaaatgaaat cagctgctgatgatgacagttcttcataaataatcggccggatagcacagatcatttgcggatttg <i>cggatgattgatcatctgaagatttag3'</i> (SEQ ID NO: 39)
BS/AI/CD154 rev	BS/AI/CD154 CotB down	5'caagaattaatcattttgaaaaaattcaatcatcatcagaagttgaaacaccgattagaattcatcatcactgaaa gaaaaatagaaaaagatattgcagcatatagagcaaaaggcaaaagttgatgcaggcaaaaaagttggtgcaaa agcagaaaaatcaaaaaaaattctggtcgttcgctcacgttca3' (SEQ ID NO: 40)

In Table 1, italicized nucleotides are those which are complementary to either side of the CotB gene insertion site of *Bacillus subtilis*.

### Electroporation

Briefly, cells were inoculated into 10 mL of LB broth and grown at 37° C. overnight. Then 100 µL of overnight culture was re-inoculated into 10 mL fresh LB broth at 37° C. for 3-4 hours. Cells were washed five times in ddH<sub>2</sub>O water and resuspended in 60 µL of 10% glycerol. Cells were then pulsed at 2.4-2.45 kV for 1-6 ms, incubated in 0.5 ml SOC for 2-3 hours at 37° C. and plated on LB media with appropriate antibiotics.

### Chromosomal Integration of Heterologous DNA for Spore Coat Expression:

Recombinant *Bacillus* strains containing stable integrated copies of selected M2e, HA and NP epitopes were constructed using recently published methods with modification. Briefly, *Bacillus* strains were transformed with the MazF cassette (Zhang et al., 2006) which generated a strain which was IPTG sensitive and spectomycin resistant. The MazF cassette flanked by approximately 300 bp of homologous DNA on each side was introduced into the CotB gene (Isticato et al., 2001) of the *Bacillus* vector by electroporation followed by growth on media containing spectomycin for positive clones which now contain the MazF cassette which is spectomycin resistant.

After the MazF mutation was confirmed in CotB, this region was replaced by a codon-optimized DNA sequence coding for the antigenic epitopes of AI again flanked by 300 bp of homologous DNA. This was done by creating a PCR product using overlapping and extension PCR to produce the antigenic sequences flanked by approximately 300 bp on each side homologous to the *Bacillus* chromosome (Cox et al., 2007). The PCR product was introduced into the *Bacillus* again by electroporation and replacement of the MazF cassette. Transformants were selected on plates containing IPTG, positive clones should now be unresponsive to IPTG

and sensitive to spectomycin. Correct chromosomal sequence insertion was confirmed by DNA sequencing.

### Example 2

#### Vaccination Study 1 and 2

Day-of-hatch (day 0) chicks were obtained from a local commercial hatchery and randomly distributed into treatment groups (n=15/treatment group, Exp 1 and n=20/treatment group, Exp 2). All chicks in each treatment group were tagged and numbered. The chicks were orally infected by gavage with 0.25 ml of saline or 10<sup>6</sup>-10<sup>8</sup> cfu/ml of the various *Bacillus* treatments as indicated in Table 2 for study 1 and in Table 3 for study 2.

TABLE 2

Challenge Dose for each treatment group in Vaccination Study 1.	
Treatment Group	Challenge Dose
Saline only	
BS/AI/HMGB1	10 <sup>6</sup> cfu/ml
BS/AI/HMGB1	10 <sup>8</sup> cfu/ml
BS/AI/CD154	10 <sup>6</sup> cfu/ml
BS/AI/CD154	10 <sup>8</sup> cfu/ml

TABLE 3

Challenge Dose for each treatment group in Vaccination Study 2.	
Treatment Group	Challenge Dose
BSBB ( <i>Bacillus</i> )	10 <sup>6</sup> cfu/ml
BS/AI/HMGB1	10 <sup>6</sup> cfu/ml

TABLE 3-continued

Challenge Dose for each treatment group in Vaccination Study 2.	
Treatment Group	Challenge Dose
BS/AI/CD154	10 <sup>6</sup> cfu/ml
BS/AI/HMGB1 Heat Inactivated	10 <sup>6</sup> cfu/ml
BS/AI/HMGB1 Formalin Inactivated	10 <sup>6</sup> cfu/ml
BS/AI/HMGB1 Antibiotic Inactivated	10 <sup>6</sup> cfu/ml
BS/AI/HMGB1 Ethanol Inactivated	10 <sup>6</sup> cfu/ml

In study 2, the bacteria were inactivated in several different ways to assess whether replication was necessary for production of an antibody response directed to the antigenic influenza peptides. Several means of inactivation were used because the means of inactivation could result in destruction of the epitope and result in misinterpretation of the data and supporting a need for replication or viability of the *Bacillus* vector. The bacteria were inactivated by incubation for 10 minutes in 0.022% formalin (formalin inactivated); incubation for 10 minutes at 70° C. (heat inactivated); incubation in 5 µg/ml gentamycin (antibiotic inactivated); or incubation for 10 minutes in 70% ethanol (ethanol inactivated).

Each treatment group was housed in an individual floor pen on fresh pine litter and provided water and feed ad libitum. On days 11 and 21 post-hatch, the birds were given a booster vaccine of the same treatment they received on Day 0. Also on days 21 and 31/32, blood was collected from each of the tagged birds and the serum was removed.

The serum collected from the tagged birds in each treatment group was then used in an antibody capture ELISA to determine specific M2e, HAUA and HALB antibody response. In brief, individual wells of a 96-well plate were coated with 10 µg/ml of the M2e epitope, HAUA epitope or HALB epitope conjugated to BSA. Antigen adhesion was allowed to proceed overnight at 4° C. Plates were rinsed with PBS+0.05% Tween 20, blocked with PBS Superblock (Pierce Chemical Co.) for a minimum of 2 hours and incubated for 2 hours with the serum previously collected from the birds in each of the treatment groups described above. The plates were rinsed with PBS+0.05% Tween 20 followed by incubation with peroxidase conjugated Goat-anti-Chicken IgY secondary antibody (1:7,500 dilution) obtained from Jackson ImmunoResearch Laboratories (West Grove, Pa.) for an additional hour. After subsequent rinsing, the plates were developed using a peroxidase substrate kit obtained from Fisher Scientific and absorbances read on a spectrophotometer at 450 nm and 405 nm.

Pooled serum samples from the groups receiving the vectored vaccine were used as positive controls and pooled serum samples from the unvaccinated groups were used as negative controls on each plate to replace the serum from the treatment groups. The absorbances obtained for the positive control, negative control and experimental samples were used to calculate Sample to Positive control ratios (S/P ratios) using the following calculation:

$$S/P \text{ ratio calculation: } \frac{\text{sample mean} - \text{negative control mean}}{\text{positive control mean} - \text{negative control mean}}$$

The calculated S/P ratios for each study are shown in FIGS. 1-6. FIGS. 1-3 show the total antibody titers for M2e, HALB and HAUA for study 1, respectively, at days 21 and 31 post-hatch. The results demonstrate that robust immune responses to each of these antigens were generated after oral administration with a *Bacillus* expressing each of the epitopes with either CD154 of HMGB1 as the immunostimulatory peptide.

FIGS. 4-6 show the total antibody titers for M2e, HALB and HAUA for study 2, respectively, at days 21 and 32 post-hatch. The results demonstrate that robust immune responses to each of the epitopes were generated after oral administration of a live *Bacillus* expressing the epitope and an immunostimulatory peptide. FIGS. 4-6 also demonstrate that similar levels of specific antibodies were generated when the vector (the *Bacillus*) was inactivated prior to administration.

#### Example 3

##### Vaccination Study 3

Day-of-hatch (day 0) chicks were obtained from a local commercial hatchery and randomly distributed into treatment groups (n=20/treatment group). All chicks in each treatment group were tagged and numbered. The chicks were orally infected by gavage with 0.25 ml of saline or 10<sup>5</sup>-10<sup>8</sup> cfu/ml of the *Bacillus* vector (BSBB), the *Bacillus* vector expressing the avian influenza epitopes and HMGB1 (BS/AI/HMGB1), or various amounts of the BS/AI/HMGB1 vector after formalin inactivation (as described above). On day 10 post-hatch, the birds were given a booster vaccine of the same treatment they received on Day 0. Also on days 21 and 32, blood was collected from each of the tagged birds and the serum was removed. The serum IgG M2e specific antibody levels were determined using the method described above with a peroxidase labeled anti-chicken IgG specific secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, Pa.). The results in FIG. 7 show that the formalin inactivated bacteria were able to stimulate production of M2e specific IgG antibodies as well as live bacteria. This result was surprising because it was generally believed that only live bacteria could stimulate a robust immune response after oral administration.

#### Example 4

##### Vaccination Study 4

Day-of-hatch (day 0) chicks were obtained from a local commercial hatchery and randomly distributed into treatment groups (n=20-35/treatment group). All chicks in each treatment group were tagged and numbered. The chicks were orally infected by gavage or injected sub-cutaneously with 0.25 ml of 10<sup>6</sup> cfu/ml of the *Bacillus* vector (BSBB), the *Bacillus* vector expressing the avian influenza epitopes and HMGB1 (BSAI), or the BSAI vector after formalin inactivation (as described above) or after formalin inactivation followed by lyophilization (reconstituted with saline immediately prior to administration). On day 10 post-hatch, some of the birds were given a booster vaccine of the same treatment they received on Day 0. On days 11, 14 and 21, blood was collected from each of the tagged birds and the serum was removed. The serum IgA and IgG M2e specific antibody levels were determined using the method described above with a peroxidase labeled anti-chicken IgA (GenTex) or a peroxidase labeled anti-chicken IgG specific secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, Pa.). The results in FIG. 8 show that the formalin inactivated bacteria were able to stimulate production of M2e specific IgA antibodies about as well as live bacteria when given orally. In contrast when given sub-cutaneously the inactivated BSAI vector was not as efficient at stimulating an IgA antibody response and the lyophilized bacteria did not stimulate an IgA response. The results in FIG. 9 show that each of the BSAI administration protocols supported robust IgG formation.

## SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 40

<210> SEQ ID NO 1  
 <211> LENGTH: 24  
 <212> TYPE: PRT  
 <213> ORGANISM: Avian influenza virus  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: M2e

<400> SEQUENCE: 1

Met Ser Leu Leu Thr Glu Val Glu Thr Pro Thr Arg Asn Gly Trp Glu  
 1                   5                   10                   15

Cys Lys Cys Ser Asp Ser Ser Asp  
 20

<210> SEQ ID NO 2  
 <211> LENGTH: 24  
 <212> TYPE: PRT  
 <213> ORGANISM: Avian Influenza virus  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: M2e

<400> SEQUENCE: 2

Met Ser Leu Leu Thr Glu Val Glu Thr Pro Thr Arg Asn Gly Trp Gly  
 1                   5                   10                   15

Cys Arg Cys Asn Asp Ser Ser Asp  
 20

<210> SEQ ID NO 3  
 <211> LENGTH: 24  
 <212> TYPE: PRT  
 <213> ORGANISM: Avian Influenza virus  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: M2e

<400> SEQUENCE: 3

Met Ser Leu Leu Thr Glu Val Glu Thr Pro Ile Arg Asn Gly Trp Gly  
 1                   5                   10                   15

Cys Arg Cys Asn Asp Ser Ser Asp  
 20

<210> SEQ ID NO 4  
 <211> LENGTH: 24  
 <212> TYPE: PRT  
 <213> ORGANISM: Avian Influenza virus  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: M2e

<400> SEQUENCE: 4

Met Ser Leu Leu Thr Glu Val Glu Thr Pro Thr Arg Asn Gly Trp Glu  
 1                   5                   10                   15

Cys Arg Cys Asn Asp Ser Ser Asp  
 20

<210> SEQ ID NO 5  
 <211> LENGTH: 8  
 <212> TYPE: PRT  
 <213> ORGANISM: Avian Influenza virus  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: M2e

-continued

---

<400> SEQUENCE: 5

Glu Val Glu Thr Pro Ile Arg Asn  
 1                    5

<210> SEQ ID NO 6  
 <211> LENGTH: 8  
 <212> TYPE: PRT  
 <213> ORGANISM: Avian Influenza virus  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: M2e

<400> SEQUENCE: 6

Glu Val Glu Thr Pro Thr Arg Asn  
 1                    5

<210> SEQ ID NO 7  
 <211> LENGTH: 12  
 <212> TYPE: PRT  
 <213> ORGANISM: Avian Influenza virus  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: HA5 UA

<400> SEQUENCE: 7

Leu Leu Ser Arg Ile Asn His Phe Glu Lys Ile Gln  
 1                    5                    10

<210> SEQ ID NO 8  
 <211> LENGTH: 19  
 <212> TYPE: PRT  
 <213> ORGANISM: Avian Influenza virus  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: HA5 LB

<400> SEQUENCE: 8

Ala Asn Pro Ala Asn Asp Leu Cys Tyr Pro Gly Asp Phe Asn Asp Tyr  
 1                    5                    10                    15

Glu Glu Leu

<210> SEQ ID NO 9  
 <211> LENGTH: 16  
 <212> TYPE: PRT  
 <213> ORGANISM: Avian Influenza virus  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: NP 54-69

<400> SEQUENCE: 9

Gly Arg Leu Ile Gln Asn Ser Ile Thr Ile Glu Arg Met Val Leu Ser  
 1                    5                    10                    15

<210> SEQ ID NO 10  
 <211> LENGTH: 14  
 <212> TYPE: PRT  
 <213> ORGANISM: Avian Influenza virus  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: NP 147-160

<400> SEQUENCE: 10

Thr Tyr Gln Arg Thr Arg Ala Leu Val Arg Thr Gly Met Asp  
 1                    5                    10

<210> SEQ ID NO 11



-continued

<211> LENGTH: 272  
 <212> TYPE: PRT  
 <213> ORGANISM: Gallus gallus  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: CD154 chicken

<400> SEQUENCE: 11

```

Met Asn Glu Ala Tyr Ser Pro Ala Ala Pro Arg Pro Met Gly Ser Thr
1          5          10          15
Ser Pro Ser Thr Met Lys Met Phe Met Cys Phe Leu Ser Val Phe Met
20          25          30
Val Val Gln Thr Ile Gly Thr Val Leu Phe Cys Leu Tyr Leu His Met
35          40          45
Lys Met Asp Lys Met Glu Glu Val Leu Ser Leu Asn Glu Asp Tyr Ile
50          55          60
Phe Leu Arg Lys Val Gln Lys Cys Gln Thr Gly Glu Asp Gln Lys Ser
65          70          75          80
Thr Leu Leu Asp Cys Glu Lys Val Leu Lys Gly Phe Gln Asp Leu Gln
85          90          95
Cys Lys Asp Arg Thr Ala Ser Glu Glu Leu Pro Lys Phe Glu Met His
100         105         110
Arg Gly His Glu His Pro His Leu Lys Ser Arg Asn Glu Thr Ser Val
115         120         125
Ala Glu Glu Lys Arg Gln Pro Ile Ala Thr His Leu Ala Gly Val Lys
130         135         140
Ser Asn Thr Thr Val Arg Val Leu Lys Trp Met Thr Thr Ser Tyr Ala
145         150         155         160
Pro Thr Ser Ser Leu Ile Ser Tyr His Glu Gly Lys Leu Lys Val Glu
165         170         175
Lys Ala Gly Leu Tyr Tyr Ile Tyr Ser Gln Val Ser Phe Cys Thr Lys
180         185         190
Ala Ala Ala Ser Ala Pro Phe Thr Leu Tyr Ile Tyr Leu Tyr Leu Pro
195         200         205
Met Glu Glu Asp Arg Leu Leu Met Lys Gly Leu Asp Thr His Ser Thr
210         215         220
Ser Thr Ala Leu Cys Glu Leu Gln Ser Ile Arg Glu Gly Gly Val Phe
225         230         235         240
Glu Leu Arg Gln Gly Asp Met Val Phe Val Asn Val Thr Asp Ser Thr
245         250         255
Ala Val Asn Val Asn Pro Gly Asn Thr Tyr Phe Gly Met Phe Lys Leu
260         265         270

```

<210> SEQ ID NO 12  
 <211> LENGTH: 261  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: Human CD154

<400> SEQUENCE: 12

```

Met Ile Glu Thr Tyr Asn Gln Thr Ser Pro Arg Ser Ala Ala Thr Gly
1          5          10          15
Leu Pro Ile Ser Met Lys Ile Phe Met Tyr Leu Leu Thr Val Phe Leu
20          25          30
Ile Thr Gln Met Ile Gly Ser Ala Leu Phe Ala Val Tyr Leu His Arg
35          40          45

```

-continued

---

Arg Leu Asp Lys Ile Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val  
 50 55 60  
 Phe Met Lys Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser  
 65 70 75 80  
 Leu Leu Asn Cys Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys  
 85 90 95  
 Asp Ile Met Leu Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu  
 100 105 110  
 Met Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser  
 115 120 125  
 Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly  
 130 135 140  
 Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln  
 145 150 155 160  
 Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr  
 165 170 175  
 Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser  
 180 185 190  
 Leu Cys Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala  
 195 200 205  
 Ala Asn Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His  
 210 215 220  
 Leu Gly Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn  
 225 230 235 240  
 Val Thr Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe  
 245 250 255  
 Gly Leu Leu Lys Leu  
 260

<210> SEQ ID NO 13  
 <211> LENGTH: 11  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: Human CD154 peptide

<400> SEQUENCE: 13

Trp Ala Glu Lys Gly Tyr Tyr Thr Met Ser Cys  
 1 5 10

<210> SEQ ID NO 14  
 <211> LENGTH: 11  
 <212> TYPE: PRT  
 <213> ORGANISM: Gallus gallus  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: Chicken CD154 peptide

<400> SEQUENCE: 14

Trp Met Thr Thr Ser Tyr Ala Pro Thr Ser Ser  
 1 5 10

<210> SEQ ID NO 15  
 <211> LENGTH: 10  
 <212> TYPE: PRT  
 <213> ORGANISM: Anas sp.  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: Duck CD154 peptide

-continued

&lt;400&gt; SEQUENCE: 15

Trp Asn Lys Thr Ser Tyr Ala Pro Met Asn  
 1 5 10

&lt;210&gt; SEQ ID NO 16

&lt;211&gt; LENGTH: 10

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Mus sp.

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: misc\_feature

&lt;223&gt; OTHER INFORMATION: Mouse CD154 peptide

&lt;400&gt; SEQUENCE: 16

Trp Ala Lys Lys Gly Tyr Tyr Thr Met Lys  
 1 5 10

&lt;210&gt; SEQ ID NO 17

&lt;211&gt; LENGTH: 10

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Bos taurus

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: misc\_feature

&lt;223&gt; OTHER INFORMATION: Cow CD154 peptide

&lt;400&gt; SEQUENCE: 17

Trp Ala Pro Lys Gly Tyr Tyr Thr Leu Ser  
 1 5 10

&lt;210&gt; SEQ ID NO 18

&lt;211&gt; LENGTH: 190

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Gallus gallus

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: misc\_feature

&lt;223&gt; OTHER INFORMATION: Chicken HMGB1 amino acid

&lt;400&gt; SEQUENCE: 18

Met Gly Lys Gly Asp Pro Lys Lys Pro Arg Gly Lys Met Ser Ser Tyr  
 1 5 10 15

Ala Phe Phe Val Gln Thr Cys Arg Glu Glu His Lys Lys Lys His Pro  
 20 25 30

Asp Ala Ser Val Asn Phe Ser Glu Phe Ser Lys Lys Cys Ser Glu Arg  
 35 40 45

Trp Lys Thr Met Ser Ser Lys Glu Lys Gly Lys Phe Glu Asp Met Ala  
 50 55 60

Lys Ala Asp Lys Leu Arg Tyr Glu Lys Glu Met Lys Asn Tyr Val Pro  
 65 70 75 80

Pro Lys Gly Glu Thr Lys Lys Lys Phe Lys Asp Pro Asn Ala Pro Lys  
 85 90 95

Arg Pro Pro Ser Ala Phe Phe Leu Phe Cys Ser Glu Phe Arg Pro Lys  
 100 105 110

Ile Lys Gly Glu His Pro Gly Leu Ser Ile Gly Asp Val Ala Lys Lys  
 115 120 125

Leu Gly Glu Met Trp Asn Asn Thr Ala Ala Asp Asp Lys Gln Pro Tyr  
 130 135 140

Glu Lys Lys Ala Ala Lys Leu Lys Glu Lys Tyr Glu Lys Asp Ile Ala  
 145 150 155 160

Ala Tyr Arg Ala Lys Gly Lys Val Asp Ala Gly Lys Lys Val Val Ala  
 165 170 175

Lys Ala Glu Lys Ser Lys Lys Lys Lys Glu Glu Glu Glu Asp

-continued

---

180 185 190

<210> SEQ ID NO 19  
 <211> LENGTH: 111  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic peptide: BS/AI/CD154 =  
 HA/NP/M2e/cCD154: SSS serine spacer

<400> SEQUENCE: 19

Ser Ser Ser Thr Tyr Gln Arg Thr Arg Ala Leu Val Arg Thr Gly Met  
 1 5 10 15  
 Asp Ser Ser Ser Ala Asn Pro Ala Asn Asp Leu Cys Tyr Pro Gly Asp  
 20 25 30  
 Phe Asn Asp Tyr Glu Glu Leu Ser Ser Ser Gly Arg Leu Ile Gln Asn  
 35 40 45  
 Ser Ile Thr Ile Glu Arg Met Val Leu Ser Ser Ser Ser Leu Leu Ser  
 50 55 60  
 Arg Ile Asn His Phe Glu Lys Ile Gln Ser Ser Ser Glu Val Glu Thr  
 65 70 75 80  
 Pro Ile Arg Asn Ser Ser Ser Glu Val Glu Thr Pro Thr Arg Asn Ser  
 85 90 95  
 Ser Ser Trp Met Thr Thr Ser Tyr Ala Pro Thr Ser Ser Ser Ser  
 100 105 110

<210> SEQ ID NO 20  
 <211> LENGTH: 302  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic peptide: BS/AI/HMGB1 =  
 HA/NP/M2e/HMGB1

<400> SEQUENCE: 20

Ser Ser Ser Thr Tyr Gln Arg Thr Arg Ala Leu Val Arg Thr Gly Met  
 1 5 10 15  
 Asp Ser Ser Ser Ala Asn Pro Ala Asn Asp Leu Cys Tyr Pro Gly Asp  
 20 25 30  
 Phe Asn Asp Tyr Glu Glu Leu Ser Ser Ser Gly Arg Leu Ile Gln Asn  
 35 40 45  
 Ser Ile Thr Ile Glu Arg Met Val Leu Ser Ser Ser Ser Leu Leu Ser  
 50 55 60  
 Arg Ile Asn His Phe Glu Lys Ile Gln Ser Ser Ser Glu Val Glu Thr  
 65 70 75 80  
 Pro Ile Arg Asn Ser Ser Ser Glu Val Glu Thr Pro Thr Arg Asn Ser  
 85 90 95  
 Ser Ser Trp Met Thr Thr Ser Tyr Ala Pro Thr Ser Ser Ser Ser Ser  
 100 105 110  
 Met Gly Lys Gly Asp Pro Lys Lys Pro Arg Gly Lys Met Ser Ser Tyr  
 115 120 125  
 Ala Phe Phe Val Gln Thr Cys Arg Glu Glu His Lys Lys Lys His Pro  
 130 135 140  
 Asp Ala Ser Val Asn Phe Ser Glu Phe Ser Lys Lys Cys Ser Glu Arg  
 145 150 155 160  
 Trp Lys Thr Met Ser Ser Lys Glu Lys Gly Lys Phe Glu Asp Met Ala  
 165 170 175  
 Lys Ala Asp Lys Leu Arg Tyr Glu Lys Glu Met Lys Asn Tyr Val Pro

-continued

---

180	185	190
Pro Lys Gly Glu Thr Lys Lys Lys Phe Lys Asp Pro Asn Ala Pro Lys		
195	200	205
Arg Pro Pro Ser Ala Phe Phe Leu Phe Cys Ser Glu Phe Arg Pro Lys		
210	215	220
Ile Lys Gly Glu His Pro Gly Leu Ser Ile Gly Asp Val Ala Lys Lys		
225	230	235
Leu Gly Glu Met Trp Asn Asn Thr Ala Ala Asp Asp Lys Gln Pro Tyr		
245	250	255
Glu Lys Lys Ala Ala Lys Leu Lys Glu Lys Tyr Glu Lys Asp Ile Ala		
260	265	270
Ala Tyr Arg Ala Lys Gly Lys Val Asp Ala Gly Lys Lys Val Val Ala		
275	280	285
Lys Ala Glu Lys Ser Lys Lys Lys Glu Glu Glu Glu Asp		
290	295	300

<210> SEQ ID NO 21  
 <211> LENGTH: 111  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic peptide: BS/AI/CD154

<400> SEQUENCE: 21

Ser Ser Ser Thr Tyr Gln Arg Thr Arg Ala Leu Val Arg Thr Gly Met
1 5 10 15
Asp Ser Ser Ser Ala Asn Pro Ala Asn Asp Leu Cys Tyr Pro Gly Asp
20 25 30
Phe Asn Asp Tyr Glu Glu Leu Ser Ser Ser Gly Arg Leu Ile Gln Asn
35 40 45
Ser Ile Thr Ile Glu Arg Met Val Leu Ser Ser Ser Ser Leu Leu Ser
50 55 60
Arg Ile Asn His Phe Glu Lys Ile Gln Ser Ser Ser Glu Val Glu Thr
65 70 75 80
Pro Ile Arg Asn Ser Ser Ser Glu Val Glu Thr Pro Thr Arg Asn Ser
85 90 95
Ser Ser Trp Met Thr Thr Ser Tyr Ala Pro Thr Ser Ser Ser Ser
100 105 110

<210> SEQ ID NO 22  
 <211> LENGTH: 290  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic peptide: BS/AI/HMGB1

<400> SEQUENCE: 22

Ser Ser Ser Thr Tyr Gln Arg Thr Arg Ala Leu Val Arg Thr Gly Met
1 5 10 15
Asp Ser Ser Ser Ala Asn Pro Ala Asn Asp Leu Cys Tyr Pro Gly Asp
20 25 30
Phe Asn Asp Tyr Glu Glu Leu Ser Ser Ser Gly Arg Leu Ile Gln Asn
35 40 45
Ser Ile Thr Ile Glu Arg Met Val Leu Ser Ser Ser Ser Leu Leu Ser
50 55 60
Arg Ile Asn His Phe Glu Lys Ile Gln Ser Ser Ser Glu Val Glu Thr
65 70 75 80

-continued

Pro Ile Arg Asn Ser Ser Ser Glu Val Glu Thr Pro Thr Arg Asn Ser  
 85 90 95  
 Ser Ser Ser Ser Met Gly Lys Gly Asp Pro Lys Lys Pro Arg Gly Lys  
 100 105 110  
 Met Ser Ser Tyr Ala Phe Phe Val Gln Thr Cys Arg Glu Glu His Lys  
 115 120 125  
 Lys Lys His Pro Asp Ala Ser Val Asn Phe Ser Glu Phe Ser Lys Lys  
 130 135 140  
 Cys Ser Glu Arg Trp Lys Thr Met Ser Ser Lys Glu Lys Gly Lys Phe  
 145 150 155 160  
 Glu Asp Met Ala Lys Ala Asp Lys Leu Arg Tyr Glu Lys Glu Met Lys  
 165 170 175  
 Asn Tyr Val Pro Pro Lys Gly Glu Thr Lys Lys Lys Phe Lys Asp Pro  
 180 185 190  
 Asn Ala Pro Lys Arg Pro Pro Ser Ala Phe Phe Leu Phe Cys Ser Glu  
 195 200 205  
 Phe Arg Pro Lys Ile Lys Gly Glu His Pro Gly Leu Ser Ile Gly Asp  
 210 215 220  
 Val Ala Lys Lys Leu Gly Glu Met Trp Asn Asn Thr Ala Ala Asp Asp  
 225 230 235 240  
 Lys Gln Pro Tyr Glu Lys Lys Ala Ala Lys Leu Lys Glu Lys Tyr Glu  
 245 250 255  
 Lys Asp Ile Ala Ala Tyr Arg Ala Lys Gly Lys Val Asp Ala Gly Lys  
 260 265 270  
 Lys Val Val Ala Lys Ala Glu Lys Ser Lys Lys Lys Lys Glu Glu Glu  
 275 280 285  
 Glu Asp  
 290

<210> SEQ ID NO 23  
 <211> LENGTH: 85  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic peptide: HMGB1 box a1

<400> SEQUENCE: 23

Met Gly Lys Gly Asp Pro Lys Lys Pro Arg Gly Lys Met Ser Ser Tyr  
 1 5 10 15  
 Ala Phe Phe Val Gln Thr Cys Arg Glu Glu His Lys Lys Lys His Pro  
 20 25 30  
 Asp Ala Ser Val Asn Phe Ser Glu Phe Ser Lys Lys Cys Ser Glu Arg  
 35 40 45  
 Trp Lys Thr Met Ser Ser Lys Glu Lys Gly Lys Phe Glu Asp Met Ala  
 50 55 60  
 Lys Ala Asp Lys Leu Arg Tyr Glu Lys Glu Met Lys Asn Tyr Val Pro  
 65 70 75 80  
 Pro Lys Gly Glu Thr  
 85

<210> SEQ ID NO 24  
 <211> LENGTH: 84  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic peptide: HMGB1 box a2

<400> SEQUENCE: 24

-continued

---

Pro Asp Ala Ser Val Asn Phe Ser Glu Phe Ser Lys Lys Cys Ser Glu  
 1                   5                   10                   15  
 Arg Trp Lys Thr Met Ser Ser Lys Glu Lys Gly Lys Phe Glu Asp Met  
           20                   25                   30  
 Ala Lys Ala Asp Lys Leu Arg Tyr Glu Lys Glu Met Lys Asn Tyr Val  
           35                   40                   45  
 Pro Pro Lys Gly Glu Thr  
           50

<210> SEQ ID NO 25  
 <211> LENGTH: 73  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic peptide: HMGB1 box b1

<400> SEQUENCE: 25

Lys Asp Pro Asn Ala Pro Lys Arg Pro Pro Ser Ala Phe Phe Leu Phe  
 1                   5                   10                   15  
 Cys Ser Glu Phe Arg Pro Lys Ile Lys Gly Glu His Pro Gly Leu Ser  
           20                   25                   30  
 Ile Gly Asp Val Ala Lys Lys Leu Gly Glu Met Trp Asn Asn Thr Ala  
           35                   40                   45  
 Ala Asp Asp Lys Gln Pro Tyr Glu Lys Lys Ala Ala Lys Leu Lys Glu  
           50                   55                   60  
 Lys Tyr Glu Lys Asp Ile Ala Ala Tyr  
           65                   70

<210> SEQ ID NO 26  
 <211> LENGTH: 69  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic peptide: HMGB1 box b2

<400> SEQUENCE: 26

Asn Ala Pro Lys Arg Pro Pro Ser Ala Phe Phe Leu Phe Cys Ser Glu  
 1                   5                   10                   15  
 Phe Arg Pro Lys Ile Lys Gly Glu His Pro Gly Leu Ser Ile Gly Asp  
           20                   25                   30  
 Val Ala Lys Lys Leu Gly Glu Met Trp Asn Asn Thr Ala Ala Asp Asp  
           35                   40                   45  
 Lys Gln Pro Tyr Glu Lys Lys Ala Ala Lys Leu Lys Glu Lys Tyr Glu  
           50                   55                   60  
 Lys Asp Ile Ala Ala  
           65

<210> SEQ ID NO 27  
 <211> LENGTH: 21  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic peptide: HMGB1 RAGE Binding domain

<400> SEQUENCE: 27

Lys Asp Pro Asn Ala Pro Lys Arg Pro Pro Ser Ala Phe Phe Leu Phe  
 1                   5                   10                   15  
 Cys Ser Glu Phe Arg  
           20

-continued

<210> SEQ ID NO 28  
 <211> LENGTH: 33  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic peptide: HMGB1 proinflammatory cytokine activity

<400> SEQUENCE: 28

Leu Lys Glu Lys Tyr Glu Lys Asp Ile Ala Ala Tyr Arg Ala Lys Gly  
 1 5 10 15

Lys Val Asp Ala Gly Lys Lys Val Val Ala Lys Ala Glu Lys Ser Lys  
 20 25 30

Lys

<210> SEQ ID NO 29  
 <211> LENGTH: 215  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: HMGB1

<400> SEQUENCE: 29

Met Gly Lys Gly Asp Pro Lys Lys Pro Arg Gly Lys Met Ser Ser Tyr  
 1 5 10 15

Ala Phe Phe Val Gln Thr Cys Arg Glu Glu His Lys Lys Lys His Pro  
 20 25 30

Asp Ala Ser Val Asn Phe Ser Glu Phe Ser Lys Lys Cys Ser Glu Arg  
 35 40 45

Trp Lys Thr Met Ser Ala Lys Glu Lys Gly Lys Phe Glu Asp Met Ala  
 50 55 60

Lys Ala Asp Lys Ala Arg Tyr Glu Arg Glu Met Lys Thr Tyr Ile Pro  
 65 70 75 80

Pro Lys Gly Glu Thr Lys Lys Lys Phe Lys Asp Pro Asn Ala Pro Lys  
 85 90 95

Arg Pro Pro Ser Ala Phe Phe Leu Phe Cys Ser Glu Tyr Arg Pro Lys  
 100 105 110

Ile Lys Gly Glu His Pro Gly Leu Ser Ile Gly Asp Val Ala Lys Lys  
 115 120 125

Leu Gly Glu Met Trp Asn Asn Thr Ala Ala Asp Asp Lys Gln Pro Tyr  
 130 135 140

Glu Lys Lys Ala Ala Lys Leu Lys Glu Lys Tyr Glu Lys Asp Ile Ala  
 145 150 155 160

Ala Tyr Arg Ala Lys Gly Lys Pro Asp Ala Ala Lys Lys Gly Val Val  
 165 170 175

Lys Ala Glu Lys Ser Lys Lys Lys Lys Glu Glu Glu Glu Asp Glu Glu  
 180 185 190

Asp Glu Glu Asp Glu Glu Glu Glu Glu Asp Glu Glu Asp Glu Asp Glu  
 195 200 205

Glu Glu Asp Asp Asp Asp Glu  
 210 215

<210> SEQ ID NO 30  
 <211> LENGTH: 205  
 <212> TYPE: PRT  
 <213> ORGANISM: Danio rerio  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature



-continued

---

<223> OTHER INFORMATION: Zebra fish HMGB1

<400> SEQUENCE: 30

Met Gly Lys Asp Pro Thr Lys Pro Arg Gly Lys Met Ser Ser Tyr Ala  
 1 5 10 15

Tyr Phe Val Gln Thr Cys Arg Glu Glu His Lys Lys Lys His Pro Glu  
 20 25 30

Ala Thr Val Asn Phe Ser Glu Phe Ser Lys Lys Cys Ser Glu Arg Trp  
 35 40 45

Lys Thr Met Ser Ala Lys Glu Lys Gly Lys Phe Glu Asp Met Ala Lys  
 50 55 60

Leu Asp Lys Ala Arg Tyr Glu Arg Glu Met Lys Asn Tyr Ile Pro Pro  
 65 70 75 80

Lys Gly Glu Lys Lys Lys Arg Phe Lys Asp Pro Asn Ala Pro Lys Arg  
 85 90 95

Pro Pro Ser Ala Phe Phe Ile Phe Cys Ser Glu Phe Arg Pro Lys Val  
 100 105 110

Lys Glu Glu Thr Pro Gly Leu Ser Ile Gly Asp Val Ala Lys Arg Leu  
 115 120 125

Gly Glu Met Trp Asn Lys Ile Ser Ser Glu Glu Lys Gln Pro Tyr Glu  
 130 135 140

Lys Lys Ala Ala Lys Leu Lys Glu Lys Tyr Glu Lys Asp Ile Ala Ala  
 145 150 155 160

Tyr Arg Ser Lys Gly Lys Val Gly Gly Gly Ala Ala Lys Ala Pro Ser  
 165 170 175

Lys Pro Asp Lys Ala Asn Asp Glu Asp Glu Asp Asp Asp Glu Glu Glu  
 180 185 190

Asp Glu Asp Asp Asp Asp Glu Glu Glu Glu Asp Asp Glu  
 195 200 205

<210> SEQ ID NO 31

<211> LENGTH: 53

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic primer: mazF for - MazF gene

<400> SEQUENCE: 31

ctaaaatctt cagatgatca atcatcctca ctgcccgctt tccagteggg aaa 53

<210> SEQ ID NO 32

<211> LENGTH: 44

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic primer: mazF rev - MazF gene

<400> SEQUENCE: 32

tgaacgtgac gaacgaccag atttccccct atgcaagggt ttat 44

<210> SEQ ID NO 33

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic primer: CotB up for - Cot B up

<400> SEQUENCE: 33

gaaatgctcg atgctgatga 20

-continued

---

<210> SEQ ID NO 34  
 <211> LENGTH: 27  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic primer: Cot B up rev - Cot B up  
  
 <400> SEQUENCE: 34  
  
 ggatgattga tcactctgaag atttttag 27

<210> SEQ ID NO 35  
 <211> LENGTH: 24  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic primer: Cot B dn for - Cot B down  
  
 <400> SEQUENCE: 35  
  
 aaatctggtc gttcgtcaccg ttca 24

<210> SEQ ID NO 36  
 <211> LENGTH: 25  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic primer: Cot B dn rev - Cot B down  
  
 <400> SEQUENCE: 36  
  
 ttacgtttcc agtgatagtc tatcg 25

<210> SEQ ID NO 37  
 <211> LENGTH: 186  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic primer: BS/AI/HMGB1 for - BS/AI/HMGB1  
 CotB up  
  
 <400> SEQUENCE: 37  
  
 aaccattcct tcaattgtaa ttgaattttg aatcagctcg cctgatgatg acagttcttc 60  
 ataatcatta aaatcgcccg gatagcacag atcatttgcc ggatttgctg atgatgaatc 120  
 catgcctggt ctaaccagtg ctctgttctt ttgatatgtg gatgattgat catctgaaga 180  
 ttttag 186

<210> SEQ ID NO 38  
 <211> LENGTH: 200  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic primer: BS/AI/HMGB1 rev - BS/AI/HMGB1  
 CotB down  
  
 <400> SEQUENCE: 38  
  
 ttacaattga aagaatggtt ctgtcatcat catcactgct gtcaagaatt aatcattttg 60  
 aaaaaattca atcatcatca gaagttgaaa caccgattag aaattcatca tcatggatga 120  
 caacatcata tgcaccgaca tcatcatcat cagaagttga aacaccgatt agaaataaat 180  
 ctggtcgttc gtcacgttca 200

<210> SEQ ID NO 39  
 <211> LENGTH: 177  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial sequence

-continued

---

```

<220> FEATURE:
<223> OTHER INFORMATION: Synthetic primer: BS/AI/CD154 for - BS/AI/CD154
      CotB up

<400> SEQUENCE: 39

ttcaaaatga ttaattcttg acagcagtga tgatgatgac agaaccattc tttcaattgt      60
aattgaattt tgaatcagtc tgacctgatga tgacagttct tcataatcat taaaatcgcc      120
cggatagcac agatcatttg cgggatttgc ggatgattga tcattctgaag atttttag      177

<210> SEQ ID NO 40
<211> LENGTH: 194
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic primer: BS/AI/CD154 rev - BS/AI/CD154
      CotB down

<400> SEQUENCE: 40

caagaattaa tcattttgaa aaaattcaat catcatcaga agttgaaaca ccgattagaa      60
attcatcatc actgaaagaa aaatatgaaa aagatattgc agcatataga gcaaaaggca      120
aagttgatgc aggcaaaaaa gttgttgcaa aagcagaaaa atcaaaaaaa aaatctggtc      180
gttcgtcacg ttca                                     194

```

---

We claim:

1. A vaccine vector comprising a first polynucleotide sequence encoding an antigenic polypeptide and a second polynucleotide sequence encoding an immunostimulatory polypeptide, wherein the vaccine vector is a bacterial vaccine vector, wherein the immunostimulatory polypeptide is an HMGB1 polypeptide, and wherein the antigenic polypeptide and the HMGB1 polypeptide are present on the surface of the vaccine vector.

2. The vaccine vector of claim 1, wherein the antigenic polypeptide is an Influenza specific polypeptide.

3. The vaccine vector of claim 2, wherein the antigenic polypeptide is an M2e, HA or NP Influenza polypeptide.

4. The vaccine vector of claim 3, wherein the antigenic polypeptide is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, an immunogenic fragment of SEQ ID NO:1, an immunogenic fragment of SEQ ID NO:2, an immunogenic fragment of SEQ ID NO:3, an immunogenic fragment of SEQ ID NO:4, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, an immunogenic fragment of SEQ ID NO: 7, an immunogenic fragment of SEQ ID NO: 8, an immunogenic fragment of SEQ ID NO: 9, and an immunogenic fragment of SEQ ID NO: 10.

5. The vaccine vector of claim 1, wherein the HMGB1 polypeptide is selected from SEQ ID NO: 18, SEQ ID NO: 29 and SEQ ID NO: 30.

6. The vaccine vector of claim 1, wherein the bacterial vaccine vector is a *Bacillus* spp.

7. The vaccine vector of claim 1, wherein the antigenic polypeptide and the HMGB1 polypeptide are linked in frame.

8. A composition comprising the vaccine vector of claim 1 and a pharmaceutically acceptable carrier.

9. The composition of claim 8, wherein the pharmaceutically acceptable carrier is acceptable for oral or nasal administration.

10. The composition of claim 8, wherein the vaccine vector is not capable of replication or is inactivated or killed.

11. A method of inducing an immune response in a subject comprising administering to the subject the vaccine vector of claim 1 in an amount effective to induce the immune response of the subject to the antigenic polypeptide.

12. The method of claim 11, wherein the vaccine vector is administered orally or intranasally.

13. The method of claim 12, wherein the immune response is an IgA antibody response to the antigenic polypeptide.

14. The method of claim 11, wherein the vaccine vector is not capable of replication in the subject or is inactivated or killed prior to administration to the subject.

15. A vaccine vector comprising a first polynucleotide sequence encoding an antigenic polypeptide present on the surface of the vaccine vector and a second polynucleotide sequence encoding an immunostimulatory polypeptide, wherein the vaccine vector is a *Bacillus* spp. and wherein the antigenic polypeptide and the immunostimulatory polypeptide are present on the surface of the vaccine vector, wherein the antigenic polypeptide is an Influenza polypeptide and wherein the immunostimulatory polypeptide is a HMGB1 polypeptide.

16. The vaccine vector of claim 15, wherein the first polynucleotide and the second polynucleotide are inserted within a third polynucleotide sequence encoding an external portion of a transmembrane protein of the *Bacillus* spp.

17. The vaccine vector of claim 15, wherein the antigenic polypeptide is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, an immunogenic fragment of SEQ ID NO:1, an immunogenic fragment of SEQ ID NO:2, an immunogenic fragment of SEQ ID NO:3, an immunogenic fragment of SEQ ID NO:4, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10.

18. The vaccine vector of claim 15, wherein the HMGB1 polypeptide is selected from SEQ ID NO: 18, SEQ ID NO: 29 and SEQ ID NO: 30.

19. A method of inducing an immune response in a subject comprising administering to the subject the vaccine vector of

claim 15 in an amount effective to induce the immune response of the subject to the Influenza polypeptide.

20. The method of claim 19, wherein the vaccine vector is administered orally or intranasally.

21. The method of claim 20, wherein the immune response is an IgA antibody response to the antigenic polypeptide. 5

22. The method of claim 19, wherein the vaccine vector is not capable of replication in the subject or is inactivated or killed prior to administration to the subject.

23. The vaccine vector of claim 15, further comprising a CD154 polypeptide comprising amino acids 140-149 of SEQ ID NO: 12. 10

24. The vaccine vector of claim 1, wherein the antigenic polypeptide and the HMGB1 polypeptide are expressed within an external loop of a transmembrane protein of the bacterial vaccine vector. 15

\* \* \* \* \*